Inari Medical (NARI) 10-Q 10 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 06, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Document Fiscal Year Focus	2021
Entity File Number	001-39293
Entity Registrant Name	Inari Medical, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2902923
Entity Address, Address Line One	9 Parker
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Irvine
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92618
City Area Code	877
Local Phone Number	923-4747
Title of 12(b) Security	Common stock, $0.001 par value per share
Trading Symbol	NARI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		49,928,519
Entity Central Index Key	0001531048
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 91,322,000	$ 114,229,000
Restricted cash	0	50,000
Short-term investments	84,744,000	49,981,000
Accounts receivable, net	31,497,000	28,008,000
Inventories	18,112,000	10,597,000
Prepaid expenses and other current assets	2,497,000	2,808,000
Total current assets	228,172,000	205,673,000
Property and equipment, net	10,827,000	7,498,000
Restricted cash	0	338,000
Operating lease right-of-use assets	868,000	0
Deposits and other assets	13,692,000	583,000
Total assets	253,559,000	214,092,000
Current liabilities
Accounts payable	10,319,000	3,047,000
Payroll-related accruals	16,041,000	8,198,000
Accrued expenses and other current liabilities	4,429,000	2,593,000
Operating lease liabilities, current portion	793,000	0
Total current liabilities	31,582,000	13,838,000
Operating lease liabilities, noncurrent portion	156,000	0
Total liabilities	31,738,000	13,838,000
Stockholders' equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2021 and December 31, 2020	0	0
Common stock, $0.001 par value, 300,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 49,828,829 and 49,251,614 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	50,000	49,000
Additional paid in capital	237,764,000	227,624,000
Accumulated other comprehensive (loss) income	(107,000)	4,000
Accumulated deficit	(15,886,000)	(27,423,000)
Total stockholders' equity	221,821,000	200,254,000
Total liabilities and stockholders' equity	$ 253,559,000	$ 214,092,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, Par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	49,828,829	49,251,614
Common stock, shares outstanding	49,828,829	49,251,614

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue	$ 63,453,000	$ 25,392,000	$ 120,850,000	$ 52,345,000
Cost of goods sold	4,814,000	3,487,000	9,437,000	6,193,000
Gross profit	58,639,000	21,905,000	111,413,000	46,152,000
Operating expenses
Research and development	11,630,000	3,628,000	19,793,000	6,646,000
Selling, general and administrative	42,897,000	18,880,000	79,795,000	35,273,000
Total operating expenses	54,527,000	22,508,000	99,588,000	41,919,000
Income from operations	4,112,000	(603,000)	11,825,000	4,233,000
Other income (expense)
Interest income	35,000	146,000	103,000	201,000
Interest expense	(74,000)	(463,000)	(147,000)	(809,000)
Change in fair value of warrant liabilities	0	2,884,000	0	(3,317,000)
Other Income Expense	7,000	0	34,000	0
Total other expenses	(32,000)	(3,201,000)	(78,000)	(3,925,000)
Income before income taxes	4,080,000	(3,804,000)	11,747,000	308,000
Provision for income taxes	12,000	0	210,000	0
Net income (loss)	4,068,000	(3,804,000)	11,537,000	308,000
Other comprehensive income (loss)
Foreign currency translation adjustments	57,000	0	(123,000)	0
Unrealized gain on available-for-sale securities	6,000	0	12,000	0
Total other comprehensive income (loss)	51,000	0	(111,000)	0
Comprehensive income	$ 4,119,000	$ (3,804,000)	$ 11,426,000	$ 308,000
Net income per share
Basic	$ 0.08	$ (0.16)	$ 0.23	$ 0.02
Diluted	$ 0.07	$ (0.16)	$ 0.21	$ 0.01
Weighted average common shares used to compute net income per share
Basic	49,669,652	24,295,900	49,512,800	15,339,755
Diluted	55,595,016	24,295,900	55,665,193	47,362,292

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Redeemable Convertible Preferred Stock
Beginning Balance at Dec. 31, 2019						$ 54,170
Beginning Balance, Shares at Dec. 31, 2019						31,968,570
Beginning Balance at Dec. 31, 2019	$ (39,144)	$ 7	$ 2,061	$ 0	$ (41,212)
Beginning Balance, Shares at Dec. 31, 2019		6,720,767
Options exercised for common stock	22	$ 0	22	0	0	$ 0
Options exercised for common stock, Shares		58,498				0
Share based compensation	495	$ 0	495	0	0	$ 0
Net income	4,112	0	0	0	4,112	0
Ending Balance at Mar. 31, 2020						$ 54,170
Ending Balance, Shares at Mar. 31, 2020						31,968,570
Ending Balance at Mar. 31, 2020	(34,515)	$ 7	2,578	0	(37,100)
Ending Balance, Shares at Mar. 31, 2020		6,779,265
Beginning Balance at Dec. 31, 2019						$ 54,170
Beginning Balance, Shares at Dec. 31, 2019						31,968,570
Beginning Balance at Dec. 31, 2019	(39,144)	$ 7	2,061	0	(41,212)
Beginning Balance, Shares at Dec. 31, 2019		6,720,767
Net income	308
Ending Balance at Jun. 30, 2020						$ 0
Ending Balance, Shares at Jun. 30, 2020						0
Ending Balance at Jun. 30, 2020	183,870	$ 48	224,726	0	(40,904)
Ending Balance, Shares at Jun. 30, 2020		48,360,081
Beginning Balance at Mar. 31, 2020						$ 54,170
Beginning Balance, Shares at Mar. 31, 2020						31,968,570
Beginning Balance at Mar. 31, 2020	(34,515)	$ 7	2,578	0	(37,100)
Beginning Balance, Shares at Mar. 31, 2020		6,779,265
Options exercised for common stock	45	$ 0	45	0	0	$ 0
Options exercised for common stock, Shares		76,764				0
Conversion of preferred stock to common stock upon initial public offering	54,170	$ 32	54,138	0	0	$ 54,170
Conversion of preferred stock to common stock upon initial public offering, Shares		31,968,570				31,968,570
Issuance of common stock in connection with initial public offering, net of issuance costs of $16.3 million	162,979	$ 9	162,970	0	0	$ 0
Issuance of common stock in connection with initial public offering, net of issuance costs of $16.3 million, Shares		9,432,949				0
Conversion and reclassification of preferred stock warrants to common stock warrants upon initial public offering	4,486	$ 0	4,486	0	0	$ 0
Exercise of common stock warrants	4	$ 0	4	0	0	$ 0
Exercise of common stock warrants, Shares		102,533				0
Share based compensation	505	$ 0	505	0	0	$ 0
Net income	(3,804)	0	0	0	3,804	0
Ending Balance at Jun. 30, 2020						$ 0
Ending Balance, Shares at Jun. 30, 2020						0
Ending Balance at Jun. 30, 2020	183,870	$ 48	224,726	0	(40,904)
Ending Balance, Shares at Jun. 30, 2020		48,360,081
Beginning Balance at Dec. 31, 2020						$ 0
Beginning Balance, Shares at Dec. 31, 2020						0
Beginning Balance at Dec. 31, 2020	200,254	$ 49	227,624	4	(27,423)
Beginning Balance, Shares at Dec. 31, 2020		49,251,614
Options exercised for common stock	381	$ 1	380	0	0	$ 0
Options exercised for common stock, Shares		296,019				0
Issuance of common stock under employee stock purchase plan	1,882	$ 0	1,882	0	0	$ 0
Issuance of common stock under employee stock purchase plan, Shares		36,881				0
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes	(49)	$ 0	(49)	0	0	$ 0
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes, Shares		901				0
Share based compensation	3,836	$ 0	3,836	0	0	$ 0
Other comprehensive income (loss)	(162)	0	0	(162)	0	0
Net income	7,469	0	0	0	7,469	0
Ending Balance at Mar. 31, 2021						$ 0
Ending Balance, Shares at Mar. 31, 2021						0
Ending Balance at Mar. 31, 2021	213,611	$ 50	233,673	(158)	(19,954)
Ending Balance, Shares at Mar. 31, 2021		49,585,415
Beginning Balance at Dec. 31, 2020						$ 0
Beginning Balance, Shares at Dec. 31, 2020						0
Beginning Balance at Dec. 31, 2020	200,254	$ 49	227,624	4	(27,423)
Beginning Balance, Shares at Dec. 31, 2020		49,251,614
Net income	11,537
Ending Balance at Jun. 30, 2021						$ 0
Ending Balance, Shares at Jun. 30, 2021						0
Ending Balance at Jun. 30, 2021	221,821	$ 50	237,764	(107)	(15,886)
Ending Balance, Shares at Jun. 30, 2021		49,828,829
Beginning Balance at Mar. 31, 2021						$ 0
Beginning Balance, Shares at Mar. 31, 2021						0
Beginning Balance at Mar. 31, 2021	213,611	$ 50	233,673	(158)	(19,954)
Beginning Balance, Shares at Mar. 31, 2021		49,585,415
Options exercised for common stock	193	$ 0	193	0	0	$ 0
Options exercised for common stock, Shares		213,605				0
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes	(706)	$ 0	(706)	0	0	$ 0
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes, Shares		29,809				0
Share based compensation	4,604	$ 0	4,604	0	0	$ 0
Other comprehensive income (loss)	51	0	0	51	0	0
Net income	4,068	0	0	0	4,068	0
Ending Balance at Jun. 30, 2021						$ 0
Ending Balance, Shares at Jun. 30, 2021						0
Ending Balance at Jun. 30, 2021	$ 221,821	$ 50	$ 237,764	$ (107)	$ (15,886)
Ending Balance, Shares at Jun. 30, 2021		49,828,829

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net income	$ 11,537	$ 308
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation	1,288	573
Amortization of deferred financing costs	76	113
Amortization of right-of-use assets	357	0
Share based compensation expense	8,440	1,000
Provision for doubtful accounts	(22)	84
Loss on change in fair value of warrant liabilities	0	3,317
Changes in:
Accounts receivable	(3,470)	(4,174)
Inventories	(7,523)	(1,667)
Prepaid expenses, deposits and other assets	(11,306)	(3,391)
Accounts payable	7,276	(255)
Payroll-related accruals, accrued expenses and other liabilities	9,796	2,287
Operating lease liabilities	(381)	0
Net cash provided by (used in) operating activities	16,068	(1,805)
Cash flows from investing activities
Purchase of property and equipment	(6,186)	(1,418)
Purchase of short-term investments	(84,751)	0
Maturity of short-term investments	50,000	0
Net cash used in investing activities	(40,937)	(1,418)
Cash flows from financing activities
Proceeds from issuance of common stock upon initial public offering, net of issuance costs paid	0	164,361
Proceeds from notes payable	0	10,000
Debt financing costs	0	(12)
Proceeds from issuance of common stock under employee stock purchase plan	1,882	0
Proceeds from exercise of stock options	573	67
Proceeds from exercise of warrants	0	4
Payment of taxes related to vested restricted stock units	(755)	0
Net cash provided by financing activities	1,700	174,420
Effect of foreign exchange rate on cash and cash equivalents	(126)	0
Net (decrease) increase in cash	(23,295)	171,197
Cash, cash equivalents and restricted cash beginning of period	114,617	24,027
Cash, cash equivalents and restricted cash end of period	91,322	195,224
Supplemental disclosures of cash flow information:
Cash paid for income taxes	158	81
Cash paid for interest	76	618
Noncash investing and financing:
Common stock issued on conversion of convertible preferred stock	0	54,170
Common stock warrants issued on conversion of preferred stock warrants and the reclassification of the warrant liability	0	4,486
Deferred initial public offering cost recorded to additional paid in capital	0	1,382
Accrual of deferred interest obligation associated with debt	$ 0	$ 100

Organization

Organization	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization	1. Organization Description of Busine ss Inari Medical, Inc. (the “Company”) was incorporated in Delaware in July 2011 and is headquartered in Irvine, California. The Company develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Initial Public Offering In May 2020, the Company completed an initial public offering (“IPO”) of its common stock. As part of the IPO, the Company issued and sold 9,432,949 shares of its common stock, which included 1,230,384 shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $ 19.00 per share. The Company received net proceeds of approximately $ 163.0 million from the IPO, after deducting underwriters’ discounts and commissions of $ 12.6 million and offering costs of $ 3.7 million, of which $ 1.4 million was incurred as of December 31, 2019. Upon the completion of the IPO, all shares of Series A, B, and C redeemable convertible preferred stock then outstanding were converted into 31,968,570 shares of common stock on a one-to-one basis. In addition, on the completion of the IPO, all the Company’s outstanding preferred stock warrants were converted into warrants to purchase an aggregate of 256,588 shares of common stock, which resulted in the reclassification of the convertible preferred stock warrant liability to additional paid-in capital. In connection with the Company’s IPO, in May 2020, the Company’s certificate of incorporation was amended and restated to provide for 300,000,000 authorized shares of common stock with a par value of $ 0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $ 0.001 per share.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies COVID-19 and the Act The global healthcare system continues to face an unprecedented challenge as a result of the novel coronavirus, or COVID-19, situation and its impact. COVID-19 is having, and may continue to have, an adverse impact on significant aspects of the Company and the business, including the demand for products, business operations, and the ability to research and develop and bring to market new products and services. The business was most acutely affected by a decline in procedural volumes during the first and second quarter of 2020, and the results for the first half of 2021 reflect some recovery from these declines the Company experienced in the first half of 2020 as a result of COVID-19. However, with cases continuing to resurge in certain areas, and hospitals at capacity in some instances due to non-COVID-19 treatments, to the extent individuals and hospital systems de-prioritize, delay or cancel deferrable medical procedures, the Company’s business, cash flows, financial condition and results of operations may continue to be negatively affected. COVID-19 has strained hospital systems around the world, resulting in adverse financial impacts to those systems, which has resulted in and may continue to result in reduced expenditures for the Company’s products. Additionally, COVID-19’s impact on our customers may adversely affect the collectability of the Company’s current and future accounts receivable balance. The Company continues to actively monitor the COVID-19 situation and its impact. In response to the pandemic, in March 2020 in the United States, governmental authorities recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled. Similarly, in March 2020, the governor of California, where the Company’s headquarters are located, issued “stay at home” orders limiting non-essential activities, travel and business operations. Such orders or restrictions significantly decreased the number of procedures performed using the Company’s products during March and April 2020 and otherwise negatively impacted operations. In response to the impact of COVID-19, the Company implemented a variety of measures to help manage through the impact and position it to resume operations quickly and efficiently once these restrictions were lifted. The Company continues to focus its efforts on the health and safety of patients, healthcare providers and employees, while executing its mission of transforming lives of venous thromboembolism ("VTE") patients. However, the Company expects the COVID-19 pandemic may continue to negatively impact 2021 performance. The Taxpayer Certainty and Disaster Tax Relief Act of 2020 ("the Act"), was enacted on December 27, 2020. It was a response to continued market volatility and instability resulting from COVID-19 and includes provisions to support businesses in the form of loans, grants, and tax changes, among other types of relief. The Company has reviewed and incorporated the income tax changes included in the Act, including the deductibility of meals expenses previously not deductible for tax purposes. We do not believe there will be a material effect on the Company’s income tax provision. The Company currently does not expect to apply for loans or grants expanded by the Act. Basis of Presentation of Unaudited Interim Condensed Consolidated Financial Statements The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain prior year reported amounts have been reclassified to conform with the 2021 presentation. The interim condensed consolidated balance sheet as of June 30, 2021, the condensed consolidated statements of operations and comprehensive income (loss), mezzanine equity and stockholders’ deficit, and cash flows for the three and six months ended June 30, 2021 and 2020 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s consolidated financial position as of June 30, 2021 and its consolidated results of operations and cash flows for the three and six months ended June 30, 2021 and 2020. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three and six months periods are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2020 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with our audited financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed on March 9, 2021. Principles of Consolidation In May 2020, the Company formed Inari Medical International, Inc., a wholly-owned subsidiary incorporated in Delaware. In September 2020, the Company formed Inari Medical Europe, GmbH, a wholly-owned subsidiary of Inari Medical International, Inc. organized in Switzerland. All intercompany balances and transactions have been eliminated in consolidation. Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to the collectability of receivables, the valuation of inventory, the fair value of common stock warrants, the fair value of preferred stock warrant liabilities, the fair value of stock options, recoverability of the Company’s net deferred tax assets and related valuation allowance, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. JOBS Act Accounting Election As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 ("the JOBS Act"), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies until such time as those standards apply to private companies. However, we will no longer qualify as an emerging growth company as of December 31, 2021 and will no longer be able to take advantage of the extended transition period. Therefore, as of December 31, 2021, we will be required to adopt new or revised accounting standards when they are applicable to public companies that are not emerging growth companies. Cash, Cash Equivalents and Restricted Cash The Company considers cash on hand, cash in demand deposit accounts including money market funds, and instruments with maturity date of 90 days or less at date of purchase to be cash equivalents. The Company maintains its cash, cash equivalent and restricted cash balances with banks. Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, deposits of up to $ 250,000 at FDIC-insured institutions are covered by FDIC insurance. At times, deposits may be in excess of the FDIC insurance limit; however, management does not believe the Company is exposed to any significant related credit risk. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): June 30, December 31, Cash and cash equivalents $ 91,322 $ 114,229 Restricted cash — 388 Total cash, cash equivalent and restricted cash $ 91,322 $ 114,617 Restricted cash as of December 31, 2020 consisted of a cash secured letter of credit in the amount of $ 338,000 representing collateral for the Company’s facility lease and a compensating balance of $ 50,000 to secure the Company’s corporate purchasing cards. In February 2021, the Company cancelled both the cash secured letter of credit and corporate purchasing card program and moved them both to its current bank, with no required cash security. Accordingly, as of June 30, 2021 , the Company had no restricted cash. Short-Term Investments Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities less than 12 months at the date of purchase are considered short-term investments. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income (loss). The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on marketable securities are included in other income (expenses), net on the condensed consolidated statements of operations. The cost of investments sold is based on the specific-identification method. Interest on marketable securities is included in interest income. Accounts Receivable, net Trade accounts receivable are recorded at the invoiced amount, net of any allowance for doubtful accounts. Any allowance for doubtful accounts, which is included in selling, general and administrative (“SG&A”) expenses, is developed based upon several factors including the customers’ credit quality, historical write-off experience and any known specific issues or disputes which exist as of the balance sheet date. Accounts receivable balances are written off against the allowance after appropriate collection efforts are exhausted. The allowance for doubtful accounts was $ 40,000 and $ 62,000 as of June 30, 2021 and December 31, 2020 , respectively, and no accounts receivable write-offs were recognized during the three and six months ended June 30, 2021 and 2020 . Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future economic and industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. The full effects of COVID-19 on the Company’s customers are highly uncertain and cannot be predicted. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s clients experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition. Inventories, net The Company values inventory at the lower of the actual cost to purchase or manufacture the inventory or net realizable value for such inventory. Cost, which includes material, labor and overhead costs, is determined on the first-in, first-out method ("FIFO"). The Company regularly reviews inventory quantities in process and on hand, and when appropriate, records a provision for obsolete and excess inventory. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements based on future demand and as compared to remaining shelf life. The estimate of excess quantities is subjective and primarily dependent on the Company’s estimates of future demand for a particular product. If the estimate of future demand is inaccurate based on actual sales, the Company may increase the write down for excess inventory for that component and record a charge to inventory impairment in the accompanying condensed consolidated statement of operations and comprehensive income (loss). Property and Equipment Property and equipment are stated at cost. Additions and improvements that extend the lives of the assets are capitalized while expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, ranging from three to seven years. Leasehold improvements are depreciated over the shorter of the useful lives of the improvements or the lease term , including renewal periods that are reasonably assured. Upon sale or disposition of property and equipment, any gain or loss is included in the accompanying condensed consolidated statement of operations. Right-of-use Assets and Lease Liabilities We determine if an arrangement contains a lease at inception and determine the classification of the lease, as either operating or finance, at commencement. Right-of-use assets and lease liabilities are recorded based on the present value of future lease payments which factors in certain qualifying initial direct costs incurred as well as any lease incentives received. If an implicit rate is not readily determinable, we utilize inputs from third-party lenders to determine the appropriate discount rate. Lease expense for operating lease payments are recognized on a straight-line basis over the lease term. Lease terms may factor in options to extend or terminate the lease. We adhere to the short-term lease recognition exemption for all classes of assets (i.e. facilities and equipment). As a result, leases with an initial term of twelve months or less are not recorded on the balance sheet and are recognized on a straight-line basis over the lease term. In addition, for certain equipment leases, we account for lease and non-lease components, such as services, as a single lease component as permitted. Impairment of Long-lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the assets. The Company has not identified any such impairment losses to date. Fair Value of Financial Instruments The Company’s cash, cash equivalents and restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their liquidity or short maturities. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. U.S. GAAP provides a fair value hierarchy that distinguishes between (i) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (ii) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels.  Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities.  Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities. See Note 3 for further information. Convertible Preferred Stock Warrant Liability The Company accounted for its freestanding warrants to purchase shares of the Company’s convertible preferred stock as liabilities at fair value upon issuance primarily because the preferred shares underlying the warrants contained contingent redemption features outside the control of the Company. The warrants were subject to remeasurement at each balance sheet date and any change in fair value was recognized as the change in fair value of warrant liability and included as a component of other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss). The carrying value of the warrants continued to be adjusted until the completion of the IPO, which occurred in May 2020. At that time, the preferred stock warrant liability was adjusted to fair value and reclassified to additional paid-in capital, a component of stockholders’ equity (deficit) (see Note 3). Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Product sales of the FlowTriever and ClotTriever systems are made to hospitals primarily in the United States utilizing the Company’s direct sales force. Revenue is comprised of product revenue net of returns, administration fees and sales rebates. Performance Obligation —The Company has revenue arrangements that consist of a single performance obligation, delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue that is recognized is based on the transaction price, which represents the invoiced amount and includes estimates of variable consideration such as rebate and administrative fees, where applicable. The Company provides a 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been immaterial to the Company’s financial statements. Assuming all other revenue recognition criteria have been met, the Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of shipping or delivering the product. For sales where the Company’s sales representatives hand deliver products directly to the hospital, control of the products transfers to the customer upon such hand delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. As of June 30, 2021 and December 31, 2020, the Company recorded $ 335,000 and $ 498,000 , respectively, of unbilled receivables, which are included in accounts receivable, net, in the accompanying condensed consolidated balance sheets. Revenue for ClotTriever and FlowTriever products as a percentage of total revenue was derived as follow: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 ClotTriever 33 % 40 % 34 % 38 % FlowTriever 67 % 60 % 66 % 62 % The Company offers payment terms to its customers of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold. Costs associated with product sales include commissions and are recorded in SG&A expenses. The Company applies the practical expedient and recognizes commissions as an expense when incurred because the amortization period is less than one year. Cost of Goods Sold Cost of goods sold consists primarily of the cost of raw materials, components, direct labor and manufacturing overhead. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management, including stock-based compensation. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalty expense. Shipping Costs Shipping costs billed to customers are not included in revenue and are reported as a reduction of costs of goods sold. Advertising Costs Advertising costs are charged to operations as incurred. Advertising costs were $ 74,000 and $ 74,000 for the three months ended June 30, 2021 and 2020, and $ 145,000 and $ 111,000 for the six months ended June 30, 2021 and 2020 , respectively. Advertising costs are included in SG&A expenses in the accompanying condensed consolidated statements of operations. Research and Development Research and development costs are expensed as incurred and include the costs to design, develop, test, deploy and enhance new and existing products. Research and development costs also include expenses associated with clinical studies, registries and sponsored research. These costs include direct salary and employee benefit related costs for research and development personnel, costs for materials used and costs for outside services. Patent-related Expenditures Expenditures related to patent research and applications, which are primarily legal fees, are expensed as incurred and are included in SG&A expenses in the accompanying condensed consolidated statements of operations. Share-based Compensation The Company’s employee and non-employee share-based awards result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest. Share-based compensation is recognized over the service period. Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance. The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of provision for income taxes. Foreign Currency Translation When the functional currencies of the Company’s foreign subsidiaries are currencies other than the U.S. dollar, the assets and liabilities of the foreign subsidiaries are translated into U.S. dollars at the exchange rate in effect on the balance sheet date. Income and expense items of the subsidiaries are translated into U.S. dollars at the average exchange rates prevailing during the period. Gains or losses from these translation adjustments are reported as a separate component of stockholders’ equity in accumulated other comprehensive income (loss) until there is a sale or complete or substantially complete liquidation of the Company’s investment in the foreign subsidiaries at which time the gains or losses will be realized and included in net income (loss). Certain vendors are paid in currencies other than the U.S. dollar. Transaction gains and losses are included in other income (expense) and have not been significant for the periods presented. Comprehensive Income (Loss) The Company’s comprehensive income (loss) is comprised of net income (loss), unrealized gains and losses on available-for-sale investments and gains and losses from foreign currency translation adjustments. Net Income (Loss) per Share of Common Stock Basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net income (loss) per share calculation, redeemable convertible preferred stock and warrants, and common stock options are potentially dilutive securities. For the periods the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive. The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The shares of the Company’s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities. Segment Reporting Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined it operates in one segment - the development and commercialization of innovative and minimally invasive mechanical thrombectomy devices to treat thromboembolism in the venous system. Geographically, the Company primarily sells to hospitals in the United States. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which expands guidance on accounting for share-based payment awards, which includes share-based payment transactions for acquiring goods and services from nonemployees and aligns the accounting for share-based payments for employees and non-employees. The Company adopted this guidance effective January 1, 2020 . The adoption of this guidance did not have a material impact on the Company’s financial statements. In February 2017, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASC 842”), as amended, which requires lessees to recognize “right of use” assets and liabilities for all leases with terms of more than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASC842 requires additional quantitative and qualitative financial statement note disclosures about the leases, significant judgments made in accounting for those leases and amounts recognized in the financial statements about those leases. The Company adopted the requirement of ASC 842 effective January 1, 2021 and elected the modified retrospective method for all lease arrangements with a cumulative-effect adjustment as of January 1, 2021. Results for reporting periods beginning on or after January 1, 2021 are presented under ASC 842, while prior period amounts were not adjusted and are reported in accordance with the Company’s historic accounting under ASC 840, Leases. For leases that commenced before the effective date of ASC 842, the Company elected the transition package of three practical expedients permitted within ASC 842, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also elected the hindsight practical expedient, which permits the use of hindsight when determining lease term and impairment of right-of-use assets. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e., leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. The Company determines if an arrangement is a lease at inception. As a lessee, right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company does not have any outstanding debt or committed credit facilities, the Company estimates the incremental borrowing rate based on prevailing financial market conditions, peer company credit analyses, and management judgment. Operating lease right-of-use assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. The lease terms used to calculate the right-of-use asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense, while the expense for finance leases is recognized as amortization expense and interest expense using the accelerated interest method of recognition. As a result of adopting ASC 842 as of January 1, 2021, the Company recorded an operating lease right-of-use asset of approximat

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2021 and December 31, 2020 (in thousands): June 30, 2021 Level 1 Level 2 Level 3 Aggregate Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 51,199 $ — $ — $ 51,199 Total included in cash and cash equivalents 51,199 — — 51,199 Marketable securities: U.S. Treasury securities 42,631 — — 42,631 Corporate debt securities and commercial paper — 42,113 — 42,113 Total included in short-term investments 42,631 42,113 — 84,744 Total assets $ 93,830 $ 42,113 $ — $ 135,943 December 31, 2020 Level 1 Level 2 Level 3 Aggregate Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 1,034 $ — $ — $ 1,034 U.S. Treasury securities 33,996 — — 33,996 Total included in cash and cash equivalents 35,030 — — 35,030 Marketable securities: U.S. Treasury securities 24,992 — — 24,992 U.S. Government agencies — 24,989 — 24,989 Total included in short-term investments 24,992 24,989 — 49,981 Total assets $ 60,022 $ 24,989 $ — $ 85,011 There were no transfers between Levels 1, 2 or 3 for the periods presented. The change in the fair value of the warrant liability is summarized below (in thousands): Six Months Ended June 30, 2021 2020 Beginning balance $ — $ 1,169 Change in fair value of warrant liability — 3,317 Conversion of preferred stock warrants to common stock — ( 4,486 ) Ending balance $ — $ — The valuation of the Company’s convertible preferred stock warrant liability contains unobservable inputs that reflect the Company’s own assumptions for which there was little, if any, market activity for at the measurement date. Accordingly, the Company’s convertible preferred stock warrant liability was measured at fair value in a recurring basis using unobservable inputs and are classified as Level 3 inputs, and any change in fair value was recognized as other expense in the statements of operations (see Note 11).

Cash Equivalents and Short-Term

Cash Equivalents and Short-Term Investments	6 Months Ended
	Jun. 30, 2021
Investments Debt And Equity Securities [Abstract]
Cash Equivalents and Short-Term Investments	4. Cash Equivalents and Short-Term Investments The following is a summary of the Company’s cash equivalents and short-term investments as of June 30, 2021 and December 31, 2020 (in thousands): June 30, 2021 Amortized Cost Basis Unrealized Gain Unrealized Loss Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 51,199 $ — $ — $ 51,199 Total included in cash and cash equivalents 51,199 — — 51,199 Marketable securities: U.S. Treasury securities 42,631 2 ( 2 ) 42,631 Corporate debt securities and commercial paper 42,096 17 — 42,113 Total included in short-term investments 84,727 19 ( 2 ) 84,744 Total assets $ 135,926 $ 19 $ ( 2 ) $ 135,943 December 31, 2020 Amortized Cost Basis Unrealized Gain Unrealized Loss Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 1,034 $ — $ — $ 1,034 U.S. Treasury securities 33,996 — — 33,996 Total included in cash and cash equivalents 35,030 — — 35,030 Marketable securities: U.S. Treasury securities 24,991 1 — 24,992 U.S. Government agencies 24,986 3 — 24,989 Total included in short-term investments 49,977 4 — 49,981 Total assets $ 85,007 $ 4 $ — $ 85,011 As of June 30, 2021 , the remaining contractual maturities for available-for-sale securities were less than one year.

Inventories, Net

Inventories, Net	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventories, Net	5. Inventories, net Inventories consist of the following (in thousands): June 30, December 31, Raw materials $ 3,730 $ 2,607 Work-in-process 2,408 787 Finished goods 11,974 7,203 $ 18,112 $ 10,597

Property and Equipment. net

Property and Equipment. net	6 Months Ended
	Jun. 30, 2021
Property Plant And Equipment [Abstract]
Property and Equipment. net	6. Property and Equipment, net Property and equipment consist of the following (in thousands): June 30, December 31, Manufacturing equipment $ 5,261 $ 4,003 Leasehold improvements 1,875 1,737 Computer software 228 128 Furniture and fixtures 377 363 Computer hardware 1,551 980 Assets in progress 4,855 2,320 14,147 9,531 Accumulated depreciation ( 3,320 ) ( 2,033 ) $ 10,827 $ 7,498 Depreciation expense of $ 522,000 and $ 218,000 was included in SG&A expenses and $ 157,000 and $ 81,000 was included in cost of goods sold for the three months ended June 30, 2021 and 2020, respectively. Depreciation expense of $ 985,000 and $ 418,000 was included in SG&A expenses and $ 303,000 and $ 155,000 was included in cost of goods sold for the six months ended June 30, 2021 and 2020 , respectively. In connection with the adoption of ASC 842, the Company reclassified $ 1,569,000 of tenant improvement costs related to the Oak Canyon lease that were deemed to be landlord assets, which were included in assets in progress as of December 31, 2020, to other assets (see Note 7). Capitalized Implementation Costs of a Hosting Arrangement The Company has several software systems that are cloud-based hosting arrangements with service contracts. The Company accounts for costs incurred in connection with the implementation of these various software systems under ASU 2018-15, Intangibles—Goodwill and Other-Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract . The Company expenses all costs (internal and external) that are incurred in the planning and post-implementation operation stages and has capitalized approximately $ 479,000 in implementation costs related to the application development stage. The capitalized costs are amortized on a straight-line basis over the non-cancelable contract terms, generally three years . As of June 30, 2021 and December 31, 2020, approximately $ 162,000 and $ 228,000 , respectively, of the capitalized costs were included in prepaid expenses and other current assets, and $ 95,000 and $ 0 , respectively, were included in deposits and other assets. The Company starts amortizing capitalized implementation costs when the systems are placed in production and ready for their intended use. Amortization expense, which was included in SG&A expenses, was approximately $ 65,000 and $ 16,000 for the three months ended June 30, 2021 and 2020 and $ 106,000 and $ 39,000 for the six months ended June 30, 2021 and 2020 , respectively.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Operating Leases The Company has operating leases for facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. Lease expense for operating leases is recognized on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASC 842, the Company combines lease and non-lease components. See Note 2, Summary of Significant Accounting Policies for additional information. In March 2019, the Company executed a five-year lease for a facility in Irvine, California, where substantially all operations of the Company have been located since September 2019. The lease expires in September 2024 and contains two optional extension periods of five years each. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The lease includes a one-month rent holiday concession and escalation clauses for increased rent over the lease term. Concurrent with the execution of a new ten-year lease (see below), the Company entered into a termination agreement (as amended) that releases the Company from the current facility lease obligation 12 months following the commencement date of the new lease, with options to extend the lease term for up to three periods of an additional 30 days each. As of June 30, 2021, the operating lease right-of-use asset and liability were $ 675,000 and $ 755,000 , respectively, with the remaining lease term of 13 months. In October 2020, the Company entered into a ten-year lease for a facility in Irvine, California (the “Oak Canyon lease”). The Company estimates that the Oak Canyon lease will have a lease commencement date in the third quarter of 2021. The Oak Canyon lease contains two optional extension periods of five years each. The Oak Canyon lease requires the Company to make variable lease payments for property taxes, insurance, maintenance, and repair costs. The Oak Canyon lease includes scheduled payment escalation clauses over the lease term. In connection with this lease, the Company has budgeted approximately $ 28 million of tenant improvement costs, $ 4.5 million of which is required to be funded by the related landlord. Because a significant portion of the tenant improvements have been deemed to be assets of the landlord and were under construction as of June 30, 2021, the Company has not yet taken control of the leased facility and the lease has not yet commenced. As of June 30, 2021, the Company has spent approximately $ 13.1 million in improvements, which are included in deposits and other assets on the condensed consolidated balance sheet. The Oak Canyon lease requires that the Company maintain a letter of credit for the benefit of the landlord in the amount of $ 1.5 million, which is secured by the Company’s Credit Agreement. The Company also leases two additional warehouse spaces located in Lake Forest and Irvine, California. As of June 30, 2021, the operating lease right-of-use assets and liabilities were $ 72,000 and $ 73,000 , respectively, with the weighted average remaining lease term of 11 months. The Company also leases certain equipment for warehouse and office use. As of June 30, 2021, the operating lease right-of-use assets and liabilities were $ 121,000 and $ 121,000 , respectively, with the weighted average remaining lease term of 48 months. As of June 30, 2021, the weighted average incremental borrowing rate used to measure operating lease liabilities was 2.9 % . During the three and six months ended June 30, 2021, cash paid for amounts included in the measurement of operating lease liabilities was $ 199,000 and $ 398,000 , respectively. Operating lease costs under the lease agreements for the three and six months ended June 30, 2021 was $ 186,000 and $ 371,000 , respectively. Future minimum lease payments under operating leases liabilities as of June 30, 2021 are as follows (in thousands): Year ending December 31: Amount Remainder of 2021 $ 406 2022 486 2023 34 2024 33 2025 16 Thereafter - Total lease payments 975 Less imputed interest ( 26 ) Total lease liabilities 949 Less: lease liabilities - current portion ( 793 ) Lease liabilities - noncurrent portion $ 156 The following are minimum future rental payments owed for the Oak Canyon lease which has not yet commenced as of June 30, 2021 (in thousands): Year ending December 31: Amount Remainder of 2021 $ 287 2022 2,050 2023 2,123 2024 2,195 2025 2,272 Thereafter 42,091 Total minimum lease payments $ 51,018 Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not been subject to any claims or required to defend any action related to its indemnification obligations. The Company’s amended and restated certificate of incorporation contains provisions limiting the liability of directors, and its amended and restated bylaws provide that the Company will indemnify each of its directors to the fullest extent permitted under Delaware law. The Company’s amended and restated certificate of incorporation and amended and restated bylaws also provide its board of directors with discretion to indemnify its officers and employees when determined appropriate by the board. In addition, the Company has entered and expects to continue to enter into agreements to indemnify its directors and executive officers. Legal Proceedings From time to time, the Company may become involved in legal proceedings arising out of the ordinary course of its business. Management is currently not aware of any matters that will have a material adverse effect on the consolidated financial position, results of operations or cash flows of the Company.

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2021
Risks And Uncertainties [Abstract]
Concentrations	8. Concentrations The Company’s revenue is derived primarily from the sale of catheter-based therapeutic devices in the United States. For the three and six months ended June 30, 2021 and 2020 , there were no customers that accounted for more than 10 % of the Company’s revenue. As of June 30, 2021 and December 31, 2020 , there were no customers that accounted for more than 10 % of the Company’s accounts receivable. No vendor accounted for more than 10 % of the Company’s purchases for the three and six months ended June 30, 2021 and 2020 . There were no vendors that accounted for more than 10 % of the Company’s accounts payable as of June 30, 2021 and December 31, 2020 .

Related Party

Related Party	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party	9. Related Party Licensed Patents Certain stockholders of the Company are stockholders of Inceptus Medical, Inc. (“Inceptus”). Beginning in September 2011, the Company engaged Inceptus to develop the technology that has led to certain components used in the Company’s products, the FlowTriever and the ClotTriever systems. In October 2014, the Company, through a license agreement with Inceptus, obtained an exclusive, perpetual, fully paid-up irrevocable, worldwide license to the patents, patent applications and technology, including the right to grant and authorize sublicenses, to make, have made, use, sell, offer for sale, import and otherwise exploit products in connection with the licensed technology. The licensed technology is any and all technology involving a high wire count braid, excluding the tubular braiding subject to the sublicense agreement described below. Sublicense Agreement In August 2019, the Company entered into a sublicense agreement with Inceptus, pursuant to which Inceptus granted to the Company a non-transferable, worldwide, exclusive sublicense to its licensed intellectual property rights related to the tubular braiding for the non-surgical removal of clots and treatment of embolism and thrombosis in human vasculature other than carotid arteries, coronary vasculature and cerebral vasculature; such rights were originally granted to Inceptus pursuant to an intellectual property license agreement with Drexel University, or Drexel License, under which Drexel retained certain rights to use, and to permit other non-commercial entities to use, the sublicensed intellectual property for educational and non-commercial research purposes. The Company is obligated to comply with, and to avoid acts or omissions that would reasonably be likely to cause a breach of the Drexel License. The sublicense agreement will continue until the expiration of the sublicensed patent, unless terminated earlier pursuant to the terms of the agreement. The Company may terminate the sublicense agreement at any time by providing prior written notice. Under the sublicense agreement, the Company is required to pay an ongoing quarterly administration fee, which amounted to $ 29,000 and $ 29,000 for the three months ended June 30, 2021 and 2020 and $ 58,000 and $ 47,000 for the six months ended June 30, 2021 and 2020 , respectively. Additionally, the Company is obligated to pay Inceptus an ongoing royalty ranging from 1 % to 1.5 % of the net sales of products utilizing the licensed intellectual property, subject to a minimum royalty quarterly fee of $ 1,000 . The Company recorded royalty expense of $ 195,000 and $ 95,000 for the three months ended June 30, 2021 and 2020, and $ 385,000 and $ 186,000 for the six months ended June 30, 2021 and 2020, respectively. Other Services The Company utilizes MRI The Hoffman Group (“MRI”), a recruiting services company owned by the brother of the Chief Executive Officer and President and member of the board of directors of the Company. The Company paid for recruiting services provided by MRI amounting to $ 129,000 and $ 170,000 for the three months ended June 30, 2021 and 2020, and $ 263,000 and $ 249,000 for the six months ended June 30, 2021 and 2020, respectively, which was included in operating expenses on the condensed consolidated statements of operations. As of June 30, 2021 and December 31, 2020 , there was no balance payable to MRI.

Debt

Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Debt	10. Debt Bank of America Credit Facility In September 2020, the Company entered into a senior secured revolving credit facility with Bank of America (the “Credit Agreement”), as amended, under which the Company may borrow loans up to a maximum principal amount of $ 30 million. The amount available to borrow under the Credit Agreement is comprised of a) 85 % of eligible accounts receivable, plus b) pledged cash (up to $10 million). There was no principal amount outstanding and no cash was pledged under the Credit Agreement as of June 30, 2021 and December 31, 2020. Advances under the Credit Agreement will bear interest at a base rate per annum (the “Base Rate”) plus an applicable margin (the “Margin”). The Base Rate equals the greater of (i) the Prime Rate, (ii) the Federal funds rate plus 0.50 % , or (iii) the LIBOR rate based upon an interest period of 30 days plus 1.00 %. The Margin ranges from 1.00 % to 1.50 % based on the Company’s applicable fixed charge coverage ratio. Advances under the Credit Agreement designated as “LIBOR Loans” will bear interest at a rate per annum equal to the LIBOR rate plus the applicable Margin ranging from 2.00 % to 2.50 % based on the Company’s applicable fixed charge coverage ratio. Interest on loans outstanding under the Credit Agreement is payable monthly . Loan principal balances outstanding under the Credit Agreement are due at maturity in September 2023 . The Company may prepay any loans under the Credit Agreement at any time without any penalty or premium. The Company is also required to pay an unused line fee at an annual rate ranging from 0.25 % to 0.375 % per annum of the average daily unused portion of the aggregate revolving credit commitments under the Credit Agreement. The Credit Agreement also includes a Letter of Credit subline facility (the “LC Facility”) of up to $ 5 million. The aggregate stated amount outstanding of letter of credits reduces the total borrowing base available under the Credit Agreement. The Company is required to pay the following fees under the LC Facility are as follows: (a) a fee equal to the applicable margin in effect for LIBOR loans (currently 2.25 %) times the average daily stated amount of outstanding letter of credits; (b) a fronting fee equal to 0.125 % per annum on the stated amount of each letter of credit outstanding. As of June 30, 2021 , the Company had two letters of credit in the aggregated amount of $ 1.8 million outstanding under the LC Facility. As of December 31, 2020 , the Company had one letter of credit in the amount of $ 1.5 million outstanding under the LC Facility. The Company paid Bank of America a closing fee of $ 150,000 and incurred approximately $ 290,000 in legal and other fees directly related to the Credit Agreement. The Credit Agreement contains certain customary covenants and events of default, including: payment defaults, breaches of any representation, warranty or covenants, judgment defaults, cross defaults to certain other contracts, certain events with respect to governmental approvals if such events could cause a material adverse change, a material impairment in the perfection or priority of the lender's security interest or in the value of the collateral, a material adverse change in the business, operations, or condition of us or any of our subsidiaries, and a material impairment of the prospect of repayment of the loans. Upon the occurrence of an event of default, a default increase in the interest rate of an additional 2.0 % could be applied to the outstanding loan balance and the lender could declare all outstanding obligations immediately due and payable and take such other actions as set forth in the loan and security agreement. The Company was in compliance with its covenant requirements as of June 30, 2021. Obligations under the Credit Agreement are secured by substantially the Company’s assets, excluding intellectual property. Signature Bank Credit Facility In December 2019, the Company entered into a $ 40 million credit facility with Signature Bank (the “SB Credit Facility”) and concurrently repaid and extinguished its term loan with East West Bank. The SB Credit Facility consisted of a term loan of up to $ 25 million and a revolving line of credit of $ 15 million. The term loan was available in two tranches: a $ 15 million tranche that was fully funded on the closing date, and a $ 10 million tranche that was available through December 2020. In March 2020, the Company borrowed an additional $ 10 million which was available under the term loan. The maturity date of the term loan was in December 2024 . Under the agreement, the Company was required to make monthly interest payments through December 2021 . The term loan bore interest at an annual rate equal to the greater of 5.50 % or the Prime Rate plus 0.50 %. Under the revolving line of credit, the Company could borrow, repay and re-borrow up to 80 % of eligible accounts receivable up to a maximum of $ 15 million. The revolving line of credit bore interest at an annual rate equal to the greater of 5.00 % or the prime rate. In August 2020, the Company repaid the SB Credit Facility in full. Deferred Financing Costs As of June 30, 2021 and December 31, 2020, costs incurred directly related to debt financings were included in deposits and other assets and are being amortized over the three-year life of the Credit Agreement on the straight-line basis as follows (in thousands): June 30, December 31, Deferred financing costs $ 430 $ 430 Accumulated amortization ( 120 ) ( 47 ) Unamortized deferred financing costs $ 310 $ 383

Stockholder's Equity

Stockholder's Equity	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Stockholder's Equity	11. Stockholder’s Equity Redeemable Convertible Preferred Stock In connection with the IPO in May 2020, the 31,968,570 shares of redeemable convertible preferred stock then outstanding were converted into 31,968,570 shares of common stock. Warrants There were no warrants outstanding as of June 30, 2021 and December 31, 2020 . The Company had previously issued common stock warrants and redeemable convertible preferred stock warrants (“Preferred Warrants”) allowing the holders to obtain shares of redeemable convertible preferred stock that contain a liquidation preference. Because this liquidation preference may have been payable in cash upon a change in control of the Company or upon exercise of redemption rights and because such a transaction was considered to be outside of the control of the Company, the Preferred Warrants were classified as liabilities in the Company’s consolidated balance sheets and were presented at their estimated fair values at each reporting date. On the completion of the IPO, all the outstanding Preferred Warrants were converted into warrants to purchase an aggregate of 256,588 shares of common stock, which resulted in the reclassification of the convertible preferred stock warrant liabilities to additional paid-in capital. In June 2020, 27,810 common stock warrants were exercised for cash. In addition, 77,030 warrants were net exercised and the Company issued 74,723 shares of common stock. In November 2020, the remaining 179,558 warrants were net exercised and the Company issued 174,776 shares of common stock. The fair value of the Preferred Warrants was determined using the Black Scholes option pricing model with the following assumptions: May 21, 2020 (1) Series A Series B Expected volatility 51.10 % 50.00 % Preferred stock fair value (per share) $ 19.00 $ 19.00 Dividend yield 0.00 % 0.00 % Risk free interest rates 0.17 % 0.53 % Expected remaining term in years 1.55 5.94 - 6.86 (1) Date the Company's registration statement on Form S-1 was declared effective.

Equity Incentive Plans

Equity Incentive Plans	6 Months Ended
	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plans	12. Equity Incentive Plans 2011 Equity Incentive Plan and 2020 Incentive Award Plan In 2011, the Company adopted the 2011 Equity Incentive Plan (the “2011 Plan”) to permit the grant of share-based awards, such as stock grants and incentives and non-qualified stock options to employees, directors, consultants and advisors. The Board has the authority to determine to whom awards will be granted, the number of shares, the term and the exercise price. In March 2020, the Company adopted the 2020 Incentive Award Plan (the “2020 Plan”), which became effective in connection with the IPO. As a result, the Company may not grant any additional awards under the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder. The Company has initially reserved 3,468,048 shares of common stock for the issuance of a variety of awards under the 2020 Plan, including stock options, stock appreciation rights, awards of restricted stock and awards of restricted stock units. In addition, the number of shares of common stock reserved for issuance under the 2020 Plan will automatically increase on the first day of January for a period of up to ten years , commencing on January 1, 2021, in an amount equal to 3 % of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company’s board of directors. As of June 30, 2021, there were 4,738,162 shares available for issuance under the 2020 Plan, including 1,477,548 additional shares reserved effective January 1, 2021. Stock Options A summary of stock option activities under the 2011 Plan for the six months ended June 30, 2021 is as follows (intrinsic value in thousands): Number of Weighted Weighted Weighted Intrinsic Outstanding, December 31, 2020 3,436,785 $ 1.36 $ 0.98 7.76 $ 295,331 Exercised ( 509,624 ) $ 1.13 $ 0.87 $ 49,258 Cancelled ( 22,191 ) $ 2.00 $ 1.29 $ 2,357 Outstanding, June 30, 2021 2,904,970 $ 1.39 $ 1.00 7.55 $ 266,928 Vested and exercisable at June 30, 2021 1,400,775 $ 0.98 $ 0.73 7.34 $ 129,288 Vested and expected to vest at June 30, 2021 2,847,163 $ 1.35 $ 0.97 7.52 $ 261,736 The aggregate intrinsic values of options outstanding, vested and exercisable, and vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company’s common stock. The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model. Restricted Stock Units In March 2019, the Company granted, under the 2011 Plan, 2,867,326 restricted stock unit awards (“RSUs”) to certain employees that vest only upon the satisfaction of both a time-based service condition and a performance-based condition. The performance-based condition is a liquidity event requirement that was satisfied on the effective date of the IPO of the Company’s common stock. The RSUs are subject to a four-year cliff vesting and will vest in March 2023. If the RSUs vest, the actual number of RSUs that will vest will be dependent on the per share value of the Company’s common stock, which is a market-based condition, determined based on the average closing price of the Company’s common stock for the three-month period immediately preceding the satisfaction of the service condition. 2020 Plan RSUs are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a four-year period with straight-line vesting and a 25 % one-year cliff or over a three-year period in equal amounts on a quarterly basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date. RSU activity under the 2020 Plan is set forth below (intrinsic value in thousands): Number of Weighted Intrinsic Outstanding, December 31, 2020 222,564 $ 58.86 $ 19,428 Granted 325,570 $ 111.05 $ 30,783 Vested ( 37,887 ) $ 52.19 $ 132 Cancelled ( 15,545 ) $ 72.59 $ 524 Outstanding, June 30, 2021 494,702 $ 88.08 $ 52,748 Total compensation cost for all share-based payment arrangements recognized, including $ 724,000 and $ 1,321,000 of stock-based compensation expense related to the ESPP for the three and six months ended June 30, 2021, respectively, was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cost of goods sold $ 202 $ 42 $ 379 $ 72 Research and development 619 77 1,021 124 Selling, general and administrative 3,783 386 7,040 804 $ 4,604 $ 505 $ 8,440 $ 1,000 Total compensation costs as of June 30, 2021 related to all non-vested awards to be recognized in future periods was $ 41,833,000 and is expected to be recognized over the remaining weighted average period of 3.4 years (See Note 16) . Employee Share Purchase Plan (ESPP) In May 2020, the Company adopted the 2020 Employee Stock Purchase Plan (“ESPP”), which became effective on the date the ESPP was adopted by the Company’s board of directors. The Company has initially reserved 990,870 shares of common stock for purchase under the ESPP. Each offering to the employees to purchase stock under the ESPP will begin on each August 1 and February 1 and will end on the following January 31 and July 31, respectively. The first offering period began on August 1, 2020 and ended on January 31, 2021 . On each purchase date, which falls on the last date of each offering period, ESPP participants will purchase shares of common stock at a price per share equal to 85 % of the lesser of (1) the fair market value per share of the common stock on the offering date or (2) the fair market value of the common stock on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Company’s Compensation Committee, in its sole discretion. The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model with the following assumptions: Six Months Ended June 30, 2021 Expected term (in years) 0.5 Expected volatility 51.91 % Dividend yield 0.00 % Risk free interest rate 0.08 % As of June 30, 2021 , 36,881 shares of common stock have been purchased under the ESPP and 1,446,505 shares are reserved for future purchases.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The following table reflects the Company’s provision (benefit) for income taxes for the periods indicated (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Income (loss) before income taxes $ 4,080 $ ( 3,804 ) $ 11,747 $ 308 Provision for income taxes 12 — 210 — Net income (loss) $ 4,068 $ ( 3,804 ) $ 11,537 $ 308 Provision for income taxes as a percentage 0.3 % 0.0 % 1.8 % 0.0 % The Company’s effective tax rate was 0.3 % and 0 % for the three months ended June 30, 2021 and 2020 , and 1.8% and 0 % for the six months ended June 30, 2021 and 2020, respectively. The Company’s effective tax rate for all periods is driven by pre-tax income, business credits, equity compensation, state taxes, and the change in valuation allowance. The Company recognized an income tax provision of $ 12,000 and $ 210,000 for the three and six months ended June 30, 2021 , respectively. There was no income tax provision (benefit) for the three and six months ended June 30, 2020. Valuation Allowance ASC 740 requires that the tax benefit of net operating losses, or NOLs, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryback or carryforward periods. As of December 31, 2020, the Company maintained a full valuation allowance of $ 11.9 million against the Company's net deferred tax assets. As of June 30, 2021, the Company believes that the deferred tax assets are currently not considered more likely than not to be realized and, accordingly, has maintained a full valuation allowance against its deferred tax assets. The Company will continue to assess its position on the realizability of its deferred tax assets, until such time as sufficient positive evidence may become available to allow the Company to reach a conclusion that a significant portion of the valuation allowance will no longer be needed. Any release of the valuation allowance will result in a material benefit recognized in the quarter of release. Uncertain Tax Positions The Company has recorded uncertain tax positions related to its federal and California research and development credit carryforwards. No interest or penalties have been recorded related to the uncertain tax positions due to available NOLs to offset the uncertain tax positions. It is not expected that there will be a significant change in uncertain tax position in the next 12 months. The Company is subject to U.S. federal and state income tax as well as to income tax in multiple state jurisdictions, and various foreign jurisdictions. In the normal course of business, the Company is subject to examination by tax authorities. As of the date of the financial statements, there are no tax examinations in progress. The statute of limitations for tax years ended after December 31, 2015 and December 31, 2016 are open for state and federal tax purposes, respectively. Taxpayer Certainty and Disaster Tax Relief Act of 2020 The Taxpayer Certainty and Disaster Tax Relief Act of 2020 ("the Act"), was enacted on December 27, 2020. It was a response to continued market volatility and instability resulting from the coronavirus pandemic and includes provisions to support businesses in the form of loans, grants, and tax changes, among other types of relief. The Company has reviewed and incorporated the income tax changes included in the Act, including the deductibility of meals expenses previously not deductible for tax purposes. The Company does not believe there will be a material effect on the its income tax provision. The Company currently does not expect to apply for loans or grants expanded by the Act.

Retirement Plan

Retirement Plan	6 Months Ended
	Jun. 30, 2021
Compensation And Retirement Disclosure [Abstract]
Retirement Plan	14. Retirement Plan In December 2017, the Company adopted the Inari Medical, Inc. 401(k) Plan which allows eligible employees after one month of service to contribute pre-tax and Roth contributions to the plan, as allowed by law. The plan assets are held by Vanguard and the plan administrator is Ascensus Trust Company. Beginning in January 2021, the Company contributes a $ 1.00 match for every $ 1.00 contributed by a participating employee up to the greater of $ 3,000 or 4 % of eligible compensation under the plan, with such Company's contributions becoming fully vested immediately. For the three and six months ended June 30, 2021, the Company recognized $ 921,000 and $ 1,759,000 in matching contributions expense.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	15. Net Income (Loss) Per Share The components of net income per share are as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Numerator: Net income (in thousands) $ 4,068 $ ( 3,804 ) $ 11,537 $ 308 Denominator: Weighted average number of common shares 49,669,652 24,295,900 49,512,800 15,339,755 Common stock equivalents from convertible — — — 25,118,162 Common stock equivalents from outstanding 2,940,337 — 3,057,128 3,663,793 Common stock equivalents from unvested RSUs 2,947,918 — 3,054,465 2,840,720 Common stock equivalents from ESPP 3,233 — 6,924 — Common stock equivalents from outstanding warrants — — — 160,001 Common stock equivalents from restricted stock 33,876 — 33,876 239,861 Weighted average number of common shares 55,595,016 24,295,900 55,665,193 47,362,292 Net income (loss) per share: Basic $ 0.08 $ ( 0.16 ) $ 0.23 $ 0.02 Diluted $ 0.07 $ ( 0.16 ) $ 0.21 $ 0.01 The following instruments were excluded for purposes of calculating weighted average common share equivalents in the computation of diluted net loss per share for the three months ended June 30, 2020 as their effect would have been anti-dilutive: Three Months Ended June 30, 2020 Convertible preferred stock 18,267,754 Common stock options 4,154,153 RSUs 2,971,864 Restricted stock subject to future vesting 239,861 Common stock warrants 179,558 25,813,190

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events In July 2021, the Company accelerated the vesting of 96,658 RSUs that had been granted under the 2011 Plan. The Company will account for the vesting acceleration as a modification under ASC 718, and will recognize a one-time stock-based compensation expense associated with this modification of approximately $ 8.3 million.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
COVID-19 and the Act	COVID-19 and the Act The global healthcare system continues to face an unprecedented challenge as a result of the novel coronavirus, or COVID-19, situation and its impact. COVID-19 is having, and may continue to have, an adverse impact on significant aspects of the Company and the business, including the demand for products, business operations, and the ability to research and develop and bring to market new products and services. The business was most acutely affected by a decline in procedural volumes during the first and second quarter of 2020, and the results for the first half of 2021 reflect some recovery from these declines the Company experienced in the first half of 2020 as a result of COVID-19. However, with cases continuing to resurge in certain areas, and hospitals at capacity in some instances due to non-COVID-19 treatments, to the extent individuals and hospital systems de-prioritize, delay or cancel deferrable medical procedures, the Company’s business, cash flows, financial condition and results of operations may continue to be negatively affected. COVID-19 has strained hospital systems around the world, resulting in adverse financial impacts to those systems, which has resulted in and may continue to result in reduced expenditures for the Company’s products. Additionally, COVID-19’s impact on our customers may adversely affect the collectability of the Company’s current and future accounts receivable balance. The Company continues to actively monitor the COVID-19 situation and its impact. In response to the pandemic, in March 2020 in the United States, governmental authorities recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled. Similarly, in March 2020, the governor of California, where the Company’s headquarters are located, issued “stay at home” orders limiting non-essential activities, travel and business operations. Such orders or restrictions significantly decreased the number of procedures performed using the Company’s products during March and April 2020 and otherwise negatively impacted operations. In response to the impact of COVID-19, the Company implemented a variety of measures to help manage through the impact and position it to resume operations quickly and efficiently once these restrictions were lifted. The Company continues to focus its efforts on the health and safety of patients, healthcare providers and employees, while executing its mission of transforming lives of venous thromboembolism ("VTE") patients. However, the Company expects the COVID-19 pandemic may continue to negatively impact 2021 performance. The Taxpayer Certainty and Disaster Tax Relief Act of 2020 ("the Act"), was enacted on December 27, 2020. It was a response to continued market volatility and instability resulting from COVID-19 and includes provisions to support businesses in the form of loans, grants, and tax changes, among other types of relief. The Company has reviewed and incorporated the income tax changes included in the Act, including the deductibility of meals expenses previously not deductible for tax purposes. We do not believe there will be a material effect on the Company’s income tax provision. The Company currently does not expect to apply for loans or grants expanded by the Act.
Basis of Presentation of Unaudited Interim Condensed Consolidated Financial Statements	Basis of Presentation of Unaudited Interim Condensed Consolidated Financial Statements The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain prior year reported amounts have been reclassified to conform with the 2021 presentation. The interim condensed consolidated balance sheet as of June 30, 2021, the condensed consolidated statements of operations and comprehensive income (loss), mezzanine equity and stockholders’ deficit, and cash flows for the three and six months ended June 30, 2021 and 2020 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s consolidated financial position as of June 30, 2021 and its consolidated results of operations and cash flows for the three and six months ended June 30, 2021 and 2020. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three and six months periods are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2020 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with our audited financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed on March 9, 2021.
Principles of Consolidation	Principles of Consolidation In May 2020, the Company formed Inari Medical International, Inc., a wholly-owned subsidiary incorporated in Delaware. In September 2020, the Company formed Inari Medical Europe, GmbH, a wholly-owned subsidiary of Inari Medical International, Inc. organized in Switzerland. All intercompany balances and transactions have been eliminated in consolidation.
Management Estimates	Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to the collectability of receivables, the valuation of inventory, the fair value of common stock warrants, the fair value of preferred stock warrant liabilities, the fair value of stock options, recoverability of the Company’s net deferred tax assets and related valuation allowance, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.
JOBS Act Accounting Election	JOBS Act Accounting Election As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 ("the JOBS Act"), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies until such time as those standards apply to private companies. However, we will no longer qualify as an emerging growth company as of December 31, 2021 and will no longer be able to take advantage of the extended transition period. Therefore, as of December 31, 2021, we will be required to adopt new or revised accounting standards when they are applicable to public companies that are not emerging growth companies.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers cash on hand, cash in demand deposit accounts including money market funds, and instruments with maturity date of 90 days or less at date of purchase to be cash equivalents. The Company maintains its cash, cash equivalent and restricted cash balances with banks. Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, deposits of up to $ 250,000 at FDIC-insured institutions are covered by FDIC insurance. At times, deposits may be in excess of the FDIC insurance limit; however, management does not believe the Company is exposed to any significant related credit risk. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): June 30, December 31, Cash and cash equivalents $ 91,322 $ 114,229 Restricted cash — 388 Total cash, cash equivalent and restricted cash $ 91,322 $ 114,617 Restricted cash as of December 31, 2020 consisted of a cash secured letter of credit in the amount of $ 338,000 representing collateral for the Company’s facility lease and a compensating balance of $ 50,000 to secure the Company’s corporate purchasing cards. In February 2021, the Company cancelled both the cash secured letter of credit and corporate purchasing card program and moved them both to its current bank, with no required cash security. Accordingly, as of June 30, 2021 , the Company had no restricted cash.
Short Term Investments	Short-Term Investments Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities less than 12 months at the date of purchase are considered short-term investments. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income (loss). The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on marketable securities are included in other income (expenses), net on the condensed consolidated statements of operations. The cost of investments sold is based on the specific-identification method. Interest on marketable securities is included in interest income.
Accounts Receivable, Net	Accounts Receivable, net Trade accounts receivable are recorded at the invoiced amount, net of any allowance for doubtful accounts. Any allowance for doubtful accounts, which is included in selling, general and administrative (“SG&A”) expenses, is developed based upon several factors including the customers’ credit quality, historical write-off experience and any known specific issues or disputes which exist as of the balance sheet date. Accounts receivable balances are written off against the allowance after appropriate collection efforts are exhausted. The allowance for doubtful accounts was $ 40,000 and $ 62,000 as of June 30, 2021 and December 31, 2020 , respectively, and no accounts receivable write-offs were recognized during the three and six months ended June 30, 2021 and 2020 . Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future economic and industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. The full effects of COVID-19 on the Company’s customers are highly uncertain and cannot be predicted. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s clients experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition.
Inventories	Inventories, net The Company values inventory at the lower of the actual cost to purchase or manufacture the inventory or net realizable value for such inventory. Cost, which includes material, labor and overhead costs, is determined on the first-in, first-out method ("FIFO"). The Company regularly reviews inventory quantities in process and on hand, and when appropriate, records a provision for obsolete and excess inventory. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements based on future demand and as compared to remaining shelf life. The estimate of excess quantities is subjective and primarily dependent on the Company’s estimates of future demand for a particular product. If the estimate of future demand is inaccurate based on actual sales, the Company may increase the write down for excess inventory for that component and record a charge to inventory impairment in the accompanying condensed consolidated statement of operations and comprehensive income (loss).
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Additions and improvements that extend the lives of the assets are capitalized while expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, ranging from three to seven years. Leasehold improvements are depreciated over the shorter of the useful lives of the improvements or the lease term , including renewal periods that are reasonably assured. Upon sale or disposition of property and equipment, any gain or loss is included in the accompanying condensed consolidated statement of operations.
Right-of-use Assets and Lease Liabilities	Right-of-use Assets and Lease Liabilities We determine if an arrangement contains a lease at inception and determine the classification of the lease, as either operating or finance, at commencement. Right-of-use assets and lease liabilities are recorded based on the present value of future lease payments which factors in certain qualifying initial direct costs incurred as well as any lease incentives received. If an implicit rate is not readily determinable, we utilize inputs from third-party lenders to determine the appropriate discount rate. Lease expense for operating lease payments are recognized on a straight-line basis over the lease term. Lease terms may factor in options to extend or terminate the lease. We adhere to the short-term lease recognition exemption for all classes of assets (i.e. facilities and equipment). As a result, leases with an initial term of twelve months or less are not recorded on the balance sheet and are recognized on a straight-line basis over the lease term. In addition, for certain equipment leases, we account for lease and non-lease components, such as services, as a single lease component as permitted.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the assets. The Company has not identified any such impairment losses to date.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s cash, cash equivalents and restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their liquidity or short maturities. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. U.S. GAAP provides a fair value hierarchy that distinguishes between (i) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (ii) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels.  Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities.  Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities. See Note 3 for further information.
Convertible Preferred Stock Warrant Liability	Convertible Preferred Stock Warrant Liability The Company accounted for its freestanding warrants to purchase shares of the Company’s convertible preferred stock as liabilities at fair value upon issuance primarily because the preferred shares underlying the warrants contained contingent redemption features outside the control of the Company. The warrants were subject to remeasurement at each balance sheet date and any change in fair value was recognized as the change in fair value of warrant liability and included as a component of other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss). The carrying value of the warrants continued to be adjusted until the completion of the IPO, which occurred in May 2020. At that time, the preferred stock warrant liability was adjusted to fair value and reclassified to additional paid-in capital, a component of stockholders’ equity (deficit) (see Note 3).
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Product sales of the FlowTriever and ClotTriever systems are made to hospitals primarily in the United States utilizing the Company’s direct sales force. Revenue is comprised of product revenue net of returns, administration fees and sales rebates. Performance Obligation —The Company has revenue arrangements that consist of a single performance obligation, delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue that is recognized is based on the transaction price, which represents the invoiced amount and includes estimates of variable consideration such as rebate and administrative fees, where applicable. The Company provides a 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been immaterial to the Company’s financial statements. Assuming all other revenue recognition criteria have been met, the Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of shipping or delivering the product. For sales where the Company’s sales representatives hand deliver products directly to the hospital, control of the products transfers to the customer upon such hand delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. As of June 30, 2021 and December 31, 2020, the Company recorded $ 335,000 and $ 498,000 , respectively, of unbilled receivables, which are included in accounts receivable, net, in the accompanying condensed consolidated balance sheets. Revenue for ClotTriever and FlowTriever products as a percentage of total revenue was derived as follow: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 ClotTriever 33 % 40 % 34 % 38 % FlowTriever 67 % 60 % 66 % 62 % The Company offers payment terms to its customers of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold. Costs associated with product sales include commissions and are recorded in SG&A expenses. The Company applies the practical expedient and recognizes commissions as an expense when incurred because the amortization period is less than one year.
Cost of Goods Sold	Cost of Goods Sold Cost of goods sold consists primarily of the cost of raw materials, components, direct labor and manufacturing overhead. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management, including stock-based compensation. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalty expense.
Shipping Costs	Shipping Costs Shipping costs billed to customers are not included in revenue and are reported as a reduction of costs of goods sold.
Advertising Costs	Advertising Costs Advertising costs are charged to operations as incurred. Advertising costs were $ 74,000 and $ 74,000 for the three months ended June 30, 2021 and 2020, and $ 145,000 and $ 111,000 for the six months ended June 30, 2021 and 2020 , respectively. Advertising costs are included in SG&A expenses in the accompanying condensed consolidated statements of operations.
Research and Development	Research and Development Research and development costs are expensed as incurred and include the costs to design, develop, test, deploy and enhance new and existing products. Research and development costs also include expenses associated with clinical studies, registries and sponsored research. These costs include direct salary and employee benefit related costs for research and development personnel, costs for materials used and costs for outside services.
Patent-Related Expenditures	Patent-related Expenditures Expenditures related to patent research and applications, which are primarily legal fees, are expensed as incurred and are included in SG&A expenses in the accompanying condensed consolidated statements of operations.
Share-based Compensation	Share-based Compensation The Company’s employee and non-employee share-based awards result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest. Share-based compensation is recognized over the service period.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance. The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of provision for income taxes.
Foreign Currency Translation	Foreign Currency Translation When the functional currencies of the Company’s foreign subsidiaries are currencies other than the U.S. dollar, the assets and liabilities of the foreign subsidiaries are translated into U.S. dollars at the exchange rate in effect on the balance sheet date. Income and expense items of the subsidiaries are translated into U.S. dollars at the average exchange rates prevailing during the period. Gains or losses from these translation adjustments are reported as a separate component of stockholders’ equity in accumulated other comprehensive income (loss) until there is a sale or complete or substantially complete liquidation of the Company’s investment in the foreign subsidiaries at which time the gains or losses will be realized and included in net income (loss). Certain vendors are paid in currencies other than the U.S. dollar. Transaction gains and losses are included in other income (expense) and have not been significant for the periods presented.
Comprehensive Income (Loss)	Comprehensive Income (Loss) The Company’s comprehensive income (loss) is comprised of net income (loss), unrealized gains and losses on available-for-sale investments and gains and losses from foreign currency translation adjustments.
Net Income (Loss) per Share of Common Stock	Net Income (Loss) per Share of Common Stock Basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net income (loss) per share calculation, redeemable convertible preferred stock and warrants, and common stock options are potentially dilutive securities. For the periods the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive. The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The shares of the Company’s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities.
Segment Reporting	Segment Reporting Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined it operates in one segment - the development and commercialization of innovative and minimally invasive mechanical thrombectomy devices to treat thromboembolism in the venous system. Geographically, the Company primarily sells to hospitals in the United States. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance.
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which expands guidance on accounting for share-based payment awards, which includes share-based payment transactions for acquiring goods and services from nonemployees and aligns the accounting for share-based payments for employees and non-employees. The Company adopted this guidance effective January 1, 2020 . The adoption of this guidance did not have a material impact on the Company’s financial statements. In February 2017, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASC 842”), as amended, which requires lessees to recognize “right of use” assets and liabilities for all leases with terms of more than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASC842 requires additional quantitative and qualitative financial statement note disclosures about the leases, significant judgments made in accounting for those leases and amounts recognized in the financial statements about those leases. The Company adopted the requirement of ASC 842 effective January 1, 2021 and elected the modified retrospective method for all lease arrangements with a cumulative-effect adjustment as of January 1, 2021. Results for reporting periods beginning on or after January 1, 2021 are presented under ASC 842, while prior period amounts were not adjusted and are reported in accordance with the Company’s historic accounting under ASC 840, Leases. For leases that commenced before the effective date of ASC 842, the Company elected the transition package of three practical expedients permitted within ASC 842, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also elected the hindsight practical expedient, which permits the use of hindsight when determining lease term and impairment of right-of-use assets. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e., leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. The Company determines if an arrangement is a lease at inception. As a lessee, right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company does not have any outstanding debt or committed credit facilities, the Company estimates the incremental borrowing rate based on prevailing financial market conditions, peer company credit analyses, and management judgment. Operating lease right-of-use assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. The lease terms used to calculate the right-of-use asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense, while the expense for finance leases is recognized as amortization expense and interest expense using the accelerated interest method of recognition. As a result of adopting ASC 842 as of January 1, 2021, the Company recorded an operating lease right-of-use asset of approximately $ 1.2 million and related operating lease liability of approximately $ 1.3 million based on the present value of the future lease payments on the date of adoption. There was no cumulative-effect adjustment recorded to retained earnings upon adoption. Adopting ASC 842 did not have a material impact on the Company’s condensed consolidated statements of operations and cash flows. See Note 7, Commitments and Contingencies, for further discussion of the Company’s adoption of ASC 842 and related disclosures. In December 2019, the FASB issued ASU 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes , which simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step-up in the tax basis of goodwill and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. ASU 2019-12 is effective for annual periods beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The Company adopted this guidance effective January 1, 2021 and the adoption of this standard did not have a material impact on its consolidated financial statements . Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments , which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. This standard provides guidance regarding methodologies and disclosures related to expected credit losses. The guidance will become effective for the Company on December 31, 2021 when the Company no longer qualifies for emerging growth company status. Management is evaluating the impact that adopting this guidance will have on the Company's consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): June 30, December 31, Cash and cash equivalents $ 91,322 $ 114,229 Restricted cash — 388 Total cash, cash equivalent and restricted cash $ 91,322 $ 114,617
Schedule of Revenue for Products as Percentage of Total Revenue	Revenue for ClotTriever and FlowTriever products as a percentage of total revenue was derived as follow: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 ClotTriever 33 % 40 % 34 % 38 % FlowTriever 67 % 60 % 66 % 62 %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value	The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2021 and December 31, 2020 (in thousands): June 30, 2021 Level 1 Level 2 Level 3 Aggregate Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 51,199 $ — $ — $ 51,199 Total included in cash and cash equivalents 51,199 — — 51,199 Marketable securities: U.S. Treasury securities 42,631 — — 42,631 Corporate debt securities and commercial paper — 42,113 — 42,113 Total included in short-term investments 42,631 42,113 — 84,744 Total assets $ 93,830 $ 42,113 $ — $ 135,943 December 31, 2020 Level 1 Level 2 Level 3 Aggregate Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 1,034 $ — $ — $ 1,034 U.S. Treasury securities 33,996 — — 33,996 Total included in cash and cash equivalents 35,030 — — 35,030 Marketable securities: U.S. Treasury securities 24,992 — — 24,992 U.S. Government agencies — 24,989 — 24,989 Total included in short-term investments 24,992 24,989 — 49,981 Total assets $ 60,022 $ 24,989 $ — $ 85,011
Schedule of Change in the Fair Value of the Warrant Liability	The change in the fair value of the warrant liability is summarized below (in thousands): Six Months Ended June 30, 2021 2020 Beginning balance $ — $ 1,169 Change in fair value of warrant liability — 3,317 Conversion of preferred stock warrants to common stock — ( 4,486 ) Ending balance $ — $ —

Cash Equivalents and Short-Te_2

Cash Equivalents and Short-Term Investments (Tables)	6 Months Ended
	Jun. 30, 2021
Investments Debt And Equity Securities [Abstract]
Summary of Cash Equivalents and Short-Term Investments	The following is a summary of the Company’s cash equivalents and short-term investments as of June 30, 2021 and December 31, 2020 (in thousands): June 30, 2021 Amortized Cost Basis Unrealized Gain Unrealized Loss Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 51,199 $ — $ — $ 51,199 Total included in cash and cash equivalents 51,199 — — 51,199 Marketable securities: U.S. Treasury securities 42,631 2 ( 2 ) 42,631 Corporate debt securities and commercial paper 42,096 17 — 42,113 Total included in short-term investments 84,727 19 ( 2 ) 84,744 Total assets $ 135,926 $ 19 $ ( 2 ) $ 135,943 December 31, 2020 Amortized Cost Basis Unrealized Gain Unrealized Loss Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 1,034 $ — $ — $ 1,034 U.S. Treasury securities 33,996 — — 33,996 Total included in cash and cash equivalents 35,030 — — 35,030 Marketable securities: U.S. Treasury securities 24,991 1 — 24,992 U.S. Government agencies 24,986 3 — 24,989 Total included in short-term investments 49,977 4 — 49,981 Total assets $ 85,007 $ 4 $ — $ 85,011

Inventories, Net (Tables)

Inventories, Net (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories, Net	Inventories consist of the following (in thousands): June 30, December 31, Raw materials $ 3,730 $ 2,607 Work-in-process 2,408 787 Finished goods 11,974 7,203 $ 18,112 $ 10,597

Property and Equipment. net (Ta

Property and Equipment. net (Tables)	6 Months Ended
	Jun. 30, 2021
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): June 30, December 31, Manufacturing equipment $ 5,261 $ 4,003 Leasehold improvements 1,875 1,737 Computer software 228 128 Furniture and fixtures 377 363 Computer hardware 1,551 980 Assets in progress 4,855 2,320 14,147 9,531 Accumulated depreciation ( 3,320 ) ( 2,033 ) $ 10,827 $ 7,498

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities	Future minimum lease payments under operating leases liabilities as of June 30, 2021 are as follows (in thousands): Year ending December 31: Amount Remainder of 2021 $ 406 2022 486 2023 34 2024 33 2025 16 Thereafter - Total lease payments 975 Less imputed interest ( 26 ) Total lease liabilities 949 Less: lease liabilities - current portion ( 793 ) Lease liabilities - noncurrent portion $ 156
Summary of Minimum Future Rental Payments on Operating Lease Not Yet Commenced	The following are minimum future rental payments owed for the Oak Canyon lease which has not yet commenced as of June 30, 2021 (in thousands): Year ending December 31: Amount Remainder of 2021 $ 287 2022 2,050 2023 2,123 2024 2,195 2025 2,272 Thereafter 42,091 Total minimum lease payments $ 51,018

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of Deferred Financing Costs	As of June 30, 2021 and December 31, 2020, costs incurred directly related to debt financings were included in deposits and other assets and are being amortized over the three-year life of the Credit Agreement on the straight-line basis as follows (in thousands): June 30, December 31, Deferred financing costs $ 430 $ 430 Accumulated amortization ( 120 ) ( 47 ) Unamortized deferred financing costs $ 310 $ 383

Stockholder's Equity (Tables)

Stockholder's Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Schedule of Fair Value of Preferred Warrants Determined Using Black Scholes Option Pricing Model	The fair value of the Preferred Warrants was determined using the Black Scholes option pricing model with the following assumptions: May 21, 2020 (1) Series A Series B Expected volatility 51.10 % 50.00 % Preferred stock fair value (per share) $ 19.00 $ 19.00 Dividend yield 0.00 % 0.00 % Risk free interest rates 0.17 % 0.53 % Expected remaining term in years 1.55 5.94 - 6.86 (1) Date the Company's registration statement on Form S-1 was declared effective.

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2021
Summary of Stock Option Activity	A summary of stock option activities under the 2011 Plan for the six months ended June 30, 2021 is as follows (intrinsic value in thousands): Number of Weighted Weighted Weighted Intrinsic Outstanding, December 31, 2020 3,436,785 $ 1.36 $ 0.98 7.76 $ 295,331 Exercised ( 509,624 ) $ 1.13 $ 0.87 $ 49,258 Cancelled ( 22,191 ) $ 2.00 $ 1.29 $ 2,357 Outstanding, June 30, 2021 2,904,970 $ 1.39 $ 1.00 7.55 $ 266,928 Vested and exercisable at June 30, 2021 1,400,775 $ 0.98 $ 0.73 7.34 $ 129,288 Vested and expected to vest at June 30, 2021 2,847,163 $ 1.35 $ 0.97 7.52 $ 261,736
Summary of RSU Activity	RSU activity under the 2020 Plan is set forth below (intrinsic value in thousands): Number of Weighted Intrinsic Outstanding, December 31, 2020 222,564 $ 58.86 $ 19,428 Granted 325,570 $ 111.05 $ 30,783 Vested ( 37,887 ) $ 52.19 $ 132 Cancelled ( 15,545 ) $ 72.59 $ 524 Outstanding, June 30, 2021 494,702 $ 88.08 $ 52,748
Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized	Total compensation cost for all share-based payment arrangements recognized, including $ 724,000 and $ 1,321,000 of stock-based compensation expense related to the ESPP for the three and six months ended June 30, 2021, respectively, was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cost of goods sold $ 202 $ 42 $ 379 $ 72 Research and development 619 77 1,021 124 Selling, general and administrative 3,783 386 7,040 804 $ 4,604 $ 505 $ 8,440 $ 1,000
2020 Employee Share Purchase Plan
Schedule of Estimated Fair Value of Option Grant and ESPP	The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model with the following assumptions: Six Months Ended June 30, 2021 Expected term (in years) 0.5 Expected volatility 51.91 % Dividend yield 0.00 % Risk free interest rate 0.08 %

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Schedule of Provision (Benefit) for Income Taxes	The following table reflects the Company’s provision (benefit) for income taxes for the periods indicated (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Income (loss) before income taxes $ 4,080 $ ( 3,804 ) $ 11,747 $ 308 Provision for income taxes 12 — 210 — Net income (loss) $ 4,068 $ ( 3,804 ) $ 11,537 $ 308 Provision for income taxes as a percentage 0.3 % 0.0 % 1.8 % 0.0 %

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Components of Net Income per Share	The components of net income per share are as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Numerator: Net income (in thousands) $ 4,068 $ ( 3,804 ) $ 11,537 $ 308 Denominator: Weighted average number of common shares 49,669,652 24,295,900 49,512,800 15,339,755 Common stock equivalents from convertible — — — 25,118,162 Common stock equivalents from outstanding 2,940,337 — 3,057,128 3,663,793 Common stock equivalents from unvested RSUs 2,947,918 — 3,054,465 2,840,720 Common stock equivalents from ESPP 3,233 — 6,924 — Common stock equivalents from outstanding warrants — — — 160,001 Common stock equivalents from restricted stock 33,876 — 33,876 239,861 Weighted average number of common shares 55,595,016 24,295,900 55,665,193 47,362,292 Net income (loss) per share: Basic $ 0.08 $ ( 0.16 ) $ 0.23 $ 0.02 Diluted $ 0.07 $ ( 0.16 ) $ 0.21 $ 0.01
Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share	The following instruments were excluded for purposes of calculating weighted average common share equivalents in the computation of diluted net loss per share for the three months ended June 30, 2020 as their effect would have been anti-dilutive: Three Months Ended June 30, 2020 Convertible preferred stock 18,267,754 Common stock options 4,154,153 RSUs 2,971,864 Restricted stock subject to future vesting 239,861 Common stock warrants 179,558 25,813,190

Organization - Additional Infor

Organization - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	May 31, 2020	Dec. 31, 2019	Dec. 31, 2020	May 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net proceeds from IPO				$ 163,000	$ 0	$ 164,361
Underwriters' discounts and commissions	$ 12,600
Offering costs	$ 3,700
Offering cost incurred		$ 1,400
Preferred stock converted into common stock	31,968,570			31,968,570
Preferred stock, conversion basis			31,968,570		Upon the completion of the IPO, all shares of Series A, B, and C redeemable convertible preferred stock then outstanding were converted into 31,968,570 shares of common stock on a one-to-one basis.
Converted into warrants to purchase common stock	256,588			256,588	256,588
Common stock, shares authorized			300,000,000		300,000,000
Common stock, par value			$ 0.001		$ 0.001
Preferred stock, shares authorized			10,000,000		10,000,000
Preferred stock, par value			$ 0.001		$ 0.001
IPO
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Stock issued	9,432,949
Public offering price	$ 19			$ 19
Common stock, shares authorized	300,000,000			300,000,000
Common stock, par value	$ 0.001			$ 0.001
Preferred stock, shares authorized	10,000,000			10,000,000
Preferred stock, par value	$ 0.001			$ 0.001
Over-allotment Option
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of stock, shares issued				1,230,384

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)Segment	Jun. 30, 2020USD ($)	Jan. 01, 2021USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2020
Summary of Significant Accounting Policies [Line Items]
Restricted cash as collateral for facility lease	$ 0		$ 0			$ 338,000
Restricted cash to secure corporate purchasing cards	0		0			50,000
Allowance for doubtful accounts	40,000		40,000			62,000
Accounts receivable write offs	0	$ 0	$ 0	$ 0
Number of operating segments | Segment			1
Operating lease right-of-use assets	868,000		$ 868,000		$ 1,200,000	0
Operating lease liability	949,000		949,000		1,300,000
Cumulative-effect adjustment recorded to retained earnings	$ (15,886,000)		$ (15,886,000)			(27,423,000)
Accounting Standards Update 2018-07
Summary of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted							true
Change in accounting principle, accounting standards update, adoption date							Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect							true
Accounting Standards Update 2016-02 | Cumulative-Effect Adjustment
Summary of Significant Accounting Policies [Line Items]
Cumulative-effect adjustment recorded to retained earnings					$ 0
Accounting Standards Update 2019-12
Summary of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true		true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2021		Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect	true		true
SG&A Expenses
Summary of Significant Accounting Policies [Line Items]
Advertising costs	$ 74,000	$ 74,000	$ 145,000	$ 111,000
Accounts Receivable, Net
Summary of Significant Accounting Policies [Line Items]
Unbilled receivables	335,000		$ 335,000			498,000
Leasehold Improvements
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives			shorter of the useful lives of the improvements or the lease term
Cash Secured Letter of Credit
Summary of Significant Accounting Policies [Line Items]
Restricted cash as collateral for facility lease						$ 338,000
Maximum
Summary of Significant Accounting Policies [Line Items]
Deposits, FDIC insured amount	$ 250,000		$ 250,000
Estimated useful lives of assets			7 years
Minimum
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives of assets			3 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 91,322	$ 114,229
Restricted cash	0	388
Total cash, cash equivalent and restricted cash	$ 91,322	$ 114,617	$ 195,224	$ 24,027

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Revenue for Products as Percentage of Total Revenue (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
ClotTriever Products
Revenue from External Customer [Line Items]
Percentage of total revenue	33.00%	40.00%	34.00%	38.00%
FlowTriever Products
Revenue from External Customer [Line Items]
Percentage of total revenue	67.00%	60.00%	66.00%	62.00%

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Level 1
Assets
Total included in cash and cash equivalents	$ 51,199	$ 35,030
Total included in short -term investments	42,631	24,992
Assets Fair Value Disclosure, Total	93,830	60,022
Level 1 | US Treasury Securities
Assets
Total included in cash and cash equivalents		33,996
Total included in short -term investments	42,631	24,992
Level 1 | U.S. Government Agencies
Assets
Total included in short -term investments		0
Level 1 | Corporate Debt Securities and Commercial Paper
Assets
Total included in short -term investments	0
Level 1 | Money Market Mutual Funds
Assets
Total included in cash and cash equivalents	51,199	1,034
Level 2
Assets
Total included in cash and cash equivalents	0	0
Total included in short -term investments	42,113	24,989
Assets Fair Value Disclosure, Total	42,113	24,989
Level 2 | US Treasury Securities
Assets
Total included in cash and cash equivalents		0
Total included in short -term investments	0	0
Level 2 | U.S. Government Agencies
Assets
Total included in short -term investments		24,989
Level 2 | Corporate Debt Securities and Commercial Paper
Assets
Total included in short -term investments	42,113
Level 2 | Money Market Mutual Funds
Assets
Total included in cash and cash equivalents	0	0
Level 3
Assets
Total included in cash and cash equivalents	0	0
Total included in short -term investments	0	0
Assets Fair Value Disclosure, Total	0	0
Level 3 | US Treasury Securities
Assets
Total included in cash and cash equivalents		0
Total included in short -term investments	0	0
Level 3 | U.S. Government Agencies
Assets
Total included in short -term investments		0
Level 3 | Corporate Debt Securities and Commercial Paper
Assets
Total included in short -term investments	0
Level 3 | Money Market Mutual Funds
Assets
Total included in cash and cash equivalents	0	0
Fair Value Measurements Recurring
Assets
Total included in cash and cash equivalents	51,199	35,030
Total included in short -term investments	84,744	49,981
Assets Fair Value Disclosure, Total	135,943	85,011
Fair Value Measurements Recurring | US Treasury Securities
Assets
Total included in cash and cash equivalents		33,996
Total included in short -term investments	42,631	24,992
Fair Value Measurements Recurring | U.S. Government Agencies
Assets
Total included in short -term investments		24,989
Fair Value Measurements Recurring | Corporate Debt Securities and Commercial Paper
Assets
Total included in short -term investments	42,113
Fair Value Measurements Recurring | Money Market Mutual Funds
Assets
Total included in cash and cash equivalents	$ 51,199	$ 1,034

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	Jun. 30, 2021USD ($)
Fair Value Disclosures [Abstract]
Fair value, assets, Level 1 to Level 2 transfers, amount	$ 0
Fair value, assets, Level 2 to Level 1 transfers, amount	0
Fair value, liabilities, Level 1 to Level 2 transfers, amount	0
Fair value, liabilities, Level 2 to Level 1 transfers, amount	$ 0

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Change in the Fair Value of the Warrant Liability (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Beginning balance	$ 0	$ 1,169
Change in fair value of warrant liability	0	3,317
Conversion of preferred stock warrants to common stock warrants upon the closing of the IPO	0	(4,486)
Ending balance	$ 0	$ 0

Cash Equivalents and Short-Te_3

Cash Equivalents and Short-Term Investments - Summary of Cash Equivalents and Short-Term Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	$ 135,926	$ 85,007
Cash Equivalents and Short-Term Investments, Unrealized Gain	19	4
Cash Equivalents and Short-Term Investments, Unrealized Loss	(2)	0
Cash Equivalents and Short-Term Investments, Fair Value	135,943	85,011
Short-Term Investments
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	84,727	49,977
Cash Equivalents and Short-Term Investments, Unrealized Gain	19	4
Cash Equivalents and Short-Term Investments, Unrealized Loss	(2)	0
Cash Equivalents and Short-Term Investments, Fair Value	84,744	49,981
Short-Term Investments | US Treasury Securities
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	42,631	24,991
Cash Equivalents and Short-Term Investments, Unrealized Gain	2	1
Cash Equivalents and Short-Term Investments, Unrealized Loss	(2)	0
Cash Equivalents and Short-Term Investments, Fair Value	42,631	24,992
Short-Term Investments | U.S. Government Agencies
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis		24,986
Cash Equivalents and Short-Term Investments, Unrealized Gain		3
Cash Equivalents and Short-Term Investments, Unrealized Loss		0
Cash Equivalents and Short-Term Investments, Fair Value		24,989
Short-Term Investments | Corporate Debt Securities and Commercial Paper
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	42,096
Cash Equivalents and Short-Term Investments, Unrealized Gain	17
Cash Equivalents and Short-Term Investments, Unrealized Loss	0
Cash Equivalents and Short-Term Investments, Fair Value	42,113
Cash and Cash Equivalents
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	51,199	35,030
Cash Equivalents and Short-Term Investments, Unrealized Gain	0	0
Cash Equivalents and Short-Term Investments, Unrealized Loss	0	0
Cash Equivalents and Short-Term Investments, Fair Value	51,199	35,030
Cash and Cash Equivalents | US Treasury Securities
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis		33,996
Cash Equivalents and Short-Term Investments, Unrealized Gain		0
Cash Equivalents and Short-Term Investments, Unrealized Loss		0
Cash Equivalents and Short-Term Investments, Fair Value		33,996
Money Market Mutual Funds | Cash and Cash Equivalents
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	51,199	1,034
Cash Equivalents and Short-Term Investments, Unrealized Gain	0	0
Cash Equivalents and Short-Term Investments, Unrealized Loss	0	0
Cash Equivalents and Short-Term Investments, Fair Value	$ 51,199	$ 1,034

Inventories, Net - Schedule of

Inventories, Net - Schedule of Inventories, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 3,730	$ 2,607
Work in process	2,408	787
Finished goods	11,974	7,203
Inventory, net	$ 18,112	$ 10,597

Property and Equipment. net - S

Property and Equipment. net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 14,147	$ 9,531
Accumulated depreciation	(3,320)	(2,033)
Property and equipment, net	10,827	7,498
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	5,261	4,003
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,875	1,737
Computer Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	228	128
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	377	363
Computer Hardware
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,551	980
Assets In Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 4,855	$ 2,320

Property and Equipment. net - A

Property and Equipment. net - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Depreciation expense			$ 1,288,000	$ 573,000
Tenant improvement reclassified to other assets	$ 13,100,000		13,100,000
Capitalized implementation cost, net	$ 479,000		$ 479,000
Capitalized implementation cost, amortization method			The capitalized costs are amortized on a straight-line basis over the non-cancelable contract terms, generally three years.
Capitalized implementation cost, amortization period	3 years		3 years
Deposits and Other Assets
Property Plant And Equipment [Line Items]
Capitalized implementation cost, current	$ 95,000,000		$ 95,000,000		$ 0
Prepaid Expenses and Other Current Assets
Property Plant And Equipment [Line Items]
Capitalized implementation cost, current	162,000		162,000		228,000
Accounting Standards Update 2016-02 | Revision of Prior Period, Accounting Standards Update, Adjustment
Property Plant And Equipment [Line Items]
Tenant improvement reclassified to other assets					$ 1,569,000
SG&A Expenses
Property Plant And Equipment [Line Items]
Depreciation expense	522,000	$ 218,000	985,000	418,000
Capitalized implementation cost, amortization	65,000	16,000	106,000	39,000
Cost of Goods Sold
Property Plant And Equipment [Line Items]
Depreciation expense	$ 157,000	$ 81,000	$ 303,000	$ 155,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	Mar. 31, 2019ExtensionPeriod	Oct. 31, 2020USD ($)ExtensionPeriod	Mar. 31, 2019	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)Warehouse	Jan. 01, 2021USD ($)	Dec. 31, 2020USD ($)
Lessee Lease Description [Line Items]
Operating lease, number of extension options | ExtensionPeriod		2
Operating lease right-of-use assets				$ 868,000	$ 868,000	$ 1,200,000	$ 0
Operating lease liability				$ 949,000	$ 949,000	$ 1,300,000
Operating lease, remaining lease term				13 months	13 months
Tenant improvement costs		$ 28,000,000
Improvements				$ 13,100,000	$ 13,100,000
Tenant improvement costs to be funded by lessor		4,500,000
Weighted average incremental borrowing rate				2.90%	2.90%
Operating lease, rent expense				$ 186,000	$ 371,000
Cash paid for amounts included in the measurement of lease liabilities				199,000	398,000
Operating lease cost				186,000	371,000
Equipment
Lessee Lease Description [Line Items]
Operating lease right-of-use assets				121,000	121,000
Operating lease liability				$ 121,000	$ 121,000
Operating lease, remaining lease term				48 months	48 months
Letter of Credit
Lessee Lease Description [Line Items]
Secured debt		$ 1,500,000
Maximum
Lessee Lease Description [Line Items]
Operating lease, term of contract	12 months		12 months
Irvine, California
Lessee Lease Description [Line Items]
Operating lease, term of contract	5 years	10 years	5 years
Operating lease, expiration date	Sep. 30, 2024
Operating lease, number of extension options | ExtensionPeriod	2
Option to extend, operating lease, term	5 years	5 years	5 years
Operating lease, Existence of option to extend		true	true
Operating lease, rent holiday concession period	1 month
Operating lease, description					The lease includes a one-month rent holiday concession and escalation clauses for increased rent over the lease term.
Operating lease right-of-use assets				$ 675,000	$ 675,000
Operating lease liability				755,000	755,000
Lake Forest, California and Irvine, California
Lessee Lease Description [Line Items]
Operating lease right-of-use assets				72,000	72,000
Operating lease liability				$ 73,000	$ 73,000
Operating lease, remaining lease term				11 months	11 months
Number of additional warehouse spaces | Warehouse					2

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Jan. 01, 2021	Dec. 31, 2020
Operating Lease Liabilities Payments Due [Abstract]
Remainder of 2021	$ 406
2022	486
2023	34
2024	33
2025	16
Thereafter	0
Total lease payments	975
Less imputed interest	(26)
Operating Lease, Liability, Total	949	$ 1,300
Less: lease liabilities - current portion	(793)		$ 0
Lease liabilities - noncurrent portion	$ 156		$ 0

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Minimum Future Rental Payments on Operating Lease Not Yet Commenced (Details) $ in Thousands	Jun. 30, 2021USD ($)
Commitments And Contingencies Disclosure [Abstract]
Remainder of 2021	$ 287
2022	2,050
2023	2,123
2024	2,195
2025	2,272
Thereafter	42,091
Total minimum lease payments	$ 51,018

Concentrations - Additional Inf

Concentrations - Additional Information (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021VendorCustomer	Jun. 30, 2020CustomerVendor	Jun. 30, 2021CustomerVendor	Jun. 30, 2020CustomerVendor	Dec. 31, 2020CustomerVendor
Revenue | Customer Concentration Risk
Concentration Risk [Line Items]
Number of customers | Customer	0	0	0	0
Concentration risk	10.00%	10.00%	10.00%	10.00%
Accounts Receivable | Customer Concentration Risk
Concentration Risk [Line Items]
Number of customers | Customer			0		0
Concentration risk			10.00%		10.00%
Purchases | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk	10.00%	10.00%	10.00%	10.00%
Number of vendor | Vendor	0	0	0	0
Accounts Payable | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk			10.00%		10.00%
Number of vendor | Vendor			0		0

Related Party - Additional Info

Related Party - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
MRI The Hoffman Group
Related Party Transaction [Line Items]
Due to related parties	$ 0		$ 0		$ 0
Inceptus
Related Party Transaction [Line Items]
Administration fee	29,000	$ 29,000	58,000	$ 47,000
Royalty expense	195,000	95,000	$ 385,000	186,000
Inceptus | Minimum
Related Party Transaction [Line Items]
Related party transaction, rate			1.00%
Royalty quarterly fee			$ 1,000
Inceptus | Maximum
Related Party Transaction [Line Items]
Related party transaction, rate			1.50%
Recruiting Services | MRI The Hoffman Group | Operating expenses
Related Party Transaction [Line Items]
Development expenses incurred	$ 129,000	$ 170,000	$ 263,000	$ 249,000

Debt - Additional Information (

Debt - Additional Information (Details)	1 Months Ended				6 Months Ended	12 Months Ended
	Dec. 31, 2021	Jun. 30, 2021USD ($)LetterOfCredit	Dec. 31, 2020USD ($)LetterOfCredit	Sep. 30, 2020USD ($)	Jun. 30, 2021USD ($)LetterOfCredit	Dec. 31, 2020USD ($)LetterOfCredit	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Number of Letter of Credit | LetterOfCredit		2	1		2	1
Bank of America Credit Facility | Credit Agreement
Debt Instrument [Line Items]
Line of credit closing fee		$ 150,000,000
Legal and other fees		$ 290,000,000
Line of credit facility covenant terms		The Credit Agreement contains certain customary covenants and events of default, including: payment defaults, breaches of any representation, warranty or covenants, judgment defaults, cross defaults to certain other contracts, certain events with respect to governmental approvals if such events could cause a material adverse change, a material impairment in the perfection or priority of the lender's security interest or in the value of the collateral, a material adverse change in the business, operations, or condition of us or any of our subsidiaries, and a material impairment of the prospect of repayment of the loans. Upon the occurrence of an event of default, a default increase in the interest rate of an additional 2.0% could be applied to the outstanding loan balance and the lender could declare all outstanding obligations immediately due and payable and take such other actions as set forth in the loan and security agreement.
Percentage of additional increase in interest rate of loan outstanding for default		2.00%
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | Credit Agreement
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				$ 30,000,000
Percentage of accounts receivable available to borrow				85.00%
Principal amount outstanding					$ 0	$ 0
Cash pledged under credit agreement		$ 0	$ 0		0	0
Interest on loans outstanding payable		monthly
Debt maturity month and year		2023-09
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | Credit Agreement | Federal Funds Rate
Debt Instrument [Line Items]
Debt instrument, description of variable rate basis		Federal funds rate plus 0.50%
Term loan variable interest rate		0.50%
Debt instrument, basis spread on variable rate		0.50%
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | Credit Agreement | LIBOR
Debt Instrument [Line Items]
Debt instrument, description of variable rate basis		the LIBOR rate based upon an interest period of 30 days plus 1.00%.
Term loan variable interest rate		1.00%
Debt instrument, basis spread on variable rate		1.00%
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | Credit Agreement | LIBOR | LIBOR Loans
Debt Instrument [Line Items]
Term loan variable interest rate		2.00%
Debt instrument, basis spread on variable rate		2.00%
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | Credit Agreement | Maximum
Debt Instrument [Line Items]
Term loan variable interest rate		1.50%
Debt instrument, basis spread on variable rate		1.50%
Unused line fee at annual rate		0.375%
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | Credit Agreement | Maximum | LIBOR | LIBOR Loans
Debt Instrument [Line Items]
Term loan variable interest rate		2.50%
Debt instrument, basis spread on variable rate		2.50%
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | Credit Agreement | Minimum
Debt Instrument [Line Items]
Term loan variable interest rate		1.00%
Debt instrument, basis spread on variable rate		1.00%
Unused line fee at annual rate		0.25%
Bank of America Credit Facility | Letter of Credit Subline Facility
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		$ 500,000			500,000
Percentage of fee on average daily stated amount of outstanding letter of credit		2.25%
Percentage of fronting fee on stated amount of each letter of credit outstanding		0.125%
Letters of credit outstanding amount		$ 1,800,000	$ 1,500,000		1,800,000	1,500,000
SB Credit Facility
Debt Instrument [Line Items]
Credit facility								$ 40,000,000
SB Credit Facility | Term Loan
Debt Instrument [Line Items]
Credit facility							$ 10,000,000	$ 25,000,000
Maturity date of credit facility	2024-12
Credit facility, frequency of periodic payment	monthly
Interest only payments period			2021-12
SB Credit Facility | Term Loan Fully Funded on Closing Date
Debt Instrument [Line Items]
Credit facility		$ 15,000,000			$ 15,000,000
SB Credit Facility | Term Loan to be Available Through December 2020
Debt Instrument [Line Items]
Credit facility			$ 10,000,000			$ 10,000,000
SB Credit Facility | Prime Rate | Term Loan
Debt Instrument [Line Items]
Term loan variable interest rate			0.50%
Debt instrument, basis spread on variable rate			0.50%
SB Credit Facility | Maximum
Debt Instrument [Line Items]
Percentage of eligible accounts receivable to borrow, repay and re-borrow debt			80.00%			80.00%
Eligible accounts receivable to borrow, repay and re-borrow debt			$ 15,000,000			$ 15,000,000
SB Credit Facility | Minimum
Debt Instrument [Line Items]
Annual interest rate of term loan			5.00%			5.00%
SB Credit Facility | Minimum | Term Loan
Debt Instrument [Line Items]
Annual interest rate of term loan		5.50%			5.50%
SB Credit Facility | Revolving Line of Credit
Debt Instrument [Line Items]
Credit facility		$ 15,000,000			$ 15,000,000

Debt - Schedule of Deferred Fin

Debt - Schedule of Deferred Financing Costs (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Deferred financing costs	$ 430	$ 430
Accumulated amortization	(120)	(47)
Unamortized deferred financing costs	$ 310	$ 383

Stockholder's Equity- Additiona

Stockholder's Equity- Additional Information (Details) - shares	Jun. 30, 2021	Dec. 31, 2020	Nov. 30, 2020	Jun. 30, 2020	May 31, 2020
Class Of Stock [Line Items]
Redeemable convertible preferred stock, shares outstanding					31,968,570
Preferred stock converted into common stock					31,968,570
Number of warrants outstanding	0	0
Converted into warrants to purchase common stock	256,588				256,588
Class of warrant exercised for cash			179,558	77,030
Number of common stock shares issued upon exercise of preferred stock warrants			174,776	74,723
Common Stock Warrants
Class Of Stock [Line Items]
Class of warrant exercised for cash				27,810

Stockholder's Equity - Schedule

Stockholder's Equity - Schedule of Fair Value of Preferred Warrants Determined Using Black Scholes Option Pricing Model (Details)	May 21, 2020$ / shares
Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Preferred stock fair value (per share)	$ 19
Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Preferred stock fair value (per share)	$ 19
Expected Volatility | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	51.10
Expected Volatility | Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	0.5000
Dividend Yield | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	0
Dividend Yield | Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	0
Risk Free Interest Rates | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	0.17
Risk Free Interest Rates | Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	0.53
Expected Remaining Term | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected remaining term in years	1 year 6 months 18 days
Expected Remaining Term | Series B | Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected remaining term in years	5 years 11 months 8 days
Expected Remaining Term | Series B | Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected remaining term in years	6 years 10 months 9 days

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Details) - USD ($)	1 Months Ended			3 Months Ended				6 Months Ended
	Jun. 30, 2021	May 31, 2020	Mar. 31, 2019	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 4,604,000		$ 505,000		$ 8,440,000	$ 1,000,000
Compensation costs related to all non-vested awards to be recognized in future	$ 41,833,000			41,833,000				$ 41,833,000
Non vested stock awards, expected remaining weighted average period								3 years 4 months 24 days
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock purchased under ESPP					36,881
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period			4 years
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 724,000				$ 1,321,000
2020 Incentive Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance							3,468,048
Percentage of annual increase in shares reserved for issuance on capital stock outstanding at year end							3.00%
Number of shares available for issuance	4,738,162			4,738,162				4,738,162
Number of shares granted								325,570
2020 Incentive Award Plan | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period								4 years
Share-based compensation vesting rights, terms								The RSUs generally vest over a four-year period with straight-line vesting and a 25% one-year cliff or over a three-year period in equal amounts on a quarterly basis, provided the employee remains continuously employed with the Company.
2020 Incentive Award Plan | Employee Stock Purchase Plan | Share Based Compensation Award Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cliff vesting, percentage								25.00%
2020 Incentive Award Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of award							10 years
2011 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance	1,477,548			1,477,548				1,477,548
2011 Equity Incentive Plan | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares granted								2,867,326
2020 Employee Share Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance	1,446,505	990,870		1,446,505				1,446,505
First offering start date		Aug. 1, 2020
First offering end date		Jan. 31, 2021
Percentage of purchase price on fair market value of common stock		85.00%
2020 Employee Share Purchase Plan | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock purchased under ESPP	36,881

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of Stock Option Activity (Details) - 2011 Equity Incentive Plan $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Number of Awards
Number of Awards, Outstanding, Beginning balance | shares	3,436,785
Number of Awards, Exercised | shares	(509,624)
Number of Awards, Cancelled | shares	(22,191)
Number of Awards, Outstanding, Ending balance | shares	2,904,970	3,436,785
Number of Awards, Vested and exercisable | shares	1,400,775
Number of Awards, Vested and expected to vest | shares	2,847,163
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 1.36
Weighted Average Exercise Price, Exercised	1.13
Weighted Average Exercise Price, Cancelled	2
Weighted Average Exercise Price, Outstanding, Ending balance	1.39	$ 1.36
Weighted Average Exercise Price, Vested and exercisable	0.98
Weighted Average Exercise Price, Vested and expected to vest	1.35
Weighted Average Fair Value
Weighted Average Fair Value, Outstanding, Beginning balance	0.98
Weighted Average Fair Value, Exercised	0.87
Weighted Average Fair Value, Cancelled	1.29
Weighted Average Fair Value, Outstanding, Ending balance	1	$ 0.98
Weighted Average Fair Value, Vested and exercisable	0.73
Weighted Average Fair Value, Vested and expected to vest	$ 0.97
Weighted Average Remaining Contractual Life (in years)
Weighted Average Remaining Contractual Life (in years), Outstanding	7 years 6 months 18 days	7 years 9 months 3 days
Weighted Average Remaining Contractual Life (in years), Vested and exercisable	7 years 4 months 2 days
Weighted Average Remaining Contractual Life (in years), Vested and expected to vest	7 years 6 months 7 days
Intrinsic Value
Intrinsic Value, Outstanding, Beginning balance | $	$ 295,331
Intrinsic Value, Exercised | $	49,258
Intrinsic Value, Cancelled | $	2,357
Intrinsic Value, Outstanding, Ending balance | $	266,928	$ 295,331
Intrinsic Value, Vested and exercisable | $	129,288
Intrinsic Value, Vested and expected to vest | $	$ 261,736

Equity Incentive Plans - Schedu

Equity Incentive Plans - Schedule of Estimated Fair Value of Option Grant and ESPP on Date of Grant (Details) - 2020 Employee Share Purchase Plan	6 Months Ended
	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected remaining term in years	6 months
Expected volatility	51.91%
Dividend yield	0.00%
Risk free interest rate	0.08%

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary of RSU Activity (Details) - 2020 Incentive Award Plan $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Number of Awards
Number of Awards, Outstanding, Beginning balance | shares	222,564
Number of shares granted | shares	325,570
Number of Awards, Vested | shares	(37,887)
Number of Awards, Cancelled | shares	(15,545)
Number of Awards, Outstanding, Ending balance | shares	494,702
Weighted Average Fair Value
Weighted Average Fair Value, Outstanding, Beginning balance | $ / shares	$ 58.86
Weighted Average Fair Value, Granted | $ / shares	111.05
Weighted Average Fair Value, Vested | $ / shares	52.19
Weighted Average Fair Value, Cancelled | $ / shares	72.59
Weighted Average Fair Value, Outstanding, Ending balance | $ / shares	$ 88.08
Intrinsic Value
Intrinsic Value, Outstanding, Beginning balance | $	$ 19,428
Intrinsic Value, Granted | $	30,783
Intrinsic Value, Vested | $	132
Intrinsic Value, Cancelled | $	524
Intrinsic Value, Outstanding, Ending balance | $	$ 52,748

Equity Incentive Plans - Sche_2

Equity Incentive Plans - Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	$ 4,604	$ 505	$ 8,440	$ 1,000
Cost of Goods Sold
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	202	42	379	72
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	619	77	1,021	124
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	$ 3,783	$ 386	$ 7,040	$ 804

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision (Benefit) for Income Taxes (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income (Loss) before income taxes	$ 4,080,000		$ (3,804,000)		$ 11,747,000	$ 308,000
Provision for income taxes	12,000		0		210,000	0
Net income (loss)	$ 4,068,000	$ 7,469,000	$ (3,804,000)	$ 4,112,000	$ 11,537,000	$ 308,000
Provision for income taxes as a percentage of income (loss) before income taxes	0.30%		0.00%		1.80%	0.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Effective tax rate	0.30%	0.00%	1.80%	0.00%
Tax provision expense	$ 12,000	$ 0	$ 210,000	$ 0
Deferred tax assets, valuation allowance					$ 11,900
Interest or penalties related to uncertain tax positions			$ 0
Significant change in unrecognized tax position, description			It is not expected that there will be a significant change in uncertain tax position in the next 12 months.
Income tax examination, description			In the normal course of business, the Company is subject to examination by tax authorities. As of the date of the financial statements, there are no tax examinations in progress. The statute of limitations for tax years ended after December 31, 2015 and December 31, 2016 are open for state and federal tax purposes, respectively.

Retirement Plan - Additional In

Retirement Plan - Additional Information (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)
Defined Benefit Plan Disclosure [Line Items]
401 (k) Plan	us-gaap:QualifiedPlanMember	us-gaap:QualifiedPlanMember
Employer contributions by plan participant		$ 1
Employee contributions by plan participant		$ 1
Participating employee eligible compensation		4.00%
Matching contribution expense recognized	$ 921,000	$ 1,759,000
Maximum
Defined Benefit Plan Disclosure [Line Items]
Participating employee up to greater		$ 3,000

Net Income (Loss) Per Share - C

Net Income (Loss) Per Share - Computation of Net Income per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Net income	$ 4,068	$ 7,469	$ (3,804)	$ 4,112	$ 11,537	$ 308
Weighted average common shares used to compute net income per share
Basic	49,669,652		24,295,900		49,512,800	15,339,755
Common stock equivalents from convertible preferred stock	0		0		0	25,118,162
Common stock equivalents from outstanding warrants	0		0		0	160,001
Weighted average number of common shares outstanding - diluted	55,595,016		24,295,900		55,665,193	47,362,292
Earnings Per Share, Basic [Abstract]
Basic	$ 0.08		$ (0.16)		$ 0.23	$ 0.02
Earnings Per Share, Diluted [Abstract]
Diluted	$ 0.07		$ (0.16)		$ 0.21	$ 0.01
Common Stock Options
Weighted average common shares used to compute net income per share
Common stock equivalents	2,940,337		0		3,057,128	3,663,793
Unvested RSUs
Weighted average common shares used to compute net income per share
Common stock equivalents	2,947,918		0		3,054,465	2,840,720
ESPP
Weighted average common shares used to compute net income per share
Common stock equivalents	3,233		0		6,924	0
Restricted Stock
Weighted average common shares used to compute net income per share
Common stock equivalents	33,876		0		33,876	239,861

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation (Details)	3 Months Ended
	Jun. 30, 2020shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	25,813,190
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	4,154,153
RSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,971,864
Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	239,861
Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	179,558
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	18,267,754

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Subsequent Event [Line Items]
Stock-based compensation expense		$ 4,604	$ 505	$ 8,440	$ 1,000
Subsequent Event
Subsequent Event [Line Items]
Stock-based compensation expense	$ 8,300
Subsequent Event | 2011 Equity Incentive Plan | Restricted Stock Units
Subsequent Event [Line Items]
Accelerated vesting, shares	96,658